<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aripiprazole (oral and long-acting injectable [Abilify Maintena]): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aripiprazole (oral and long-acting injectable [Abilify Maintena]): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aripiprazole (oral and long-acting injectable [Abilify Maintena]): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8786" href="/d/html/8786.html" rel="external">see "Aripiprazole (oral and long-acting injectable [Abilify Maintena]): Drug information"</a> and <a class="drug drug_patient" data-topicid="10978" href="/d/html/10978.html" rel="external">see "Aripiprazole (oral and long-acting injectable [Abilify Maintena]): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708627"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased mortality in elderly patients with dementia-related psychosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidality and antidepressant drugs:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients older than 24 years of age; there was a reduction in risk with antidepressant use in patients 65 years of age and older. Closely monitor all antidepressant-treated patients for clinical worsening and for the emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. The safety and efficacy of aripiprazole tablets with sensor have not been established in pediatric patients.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F136801"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Abilify;</li>
<li>Abilify Asimtufii;</li>
<li>Abilify Maintena;</li>
<li>Abilify MyCite Maintenance Kit;</li>
<li>Abilify MyCite Starter Kit;</li>
<li>Abilify MyCite [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865977"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Abilify;</li>
<li>Abilify Maintena;</li>
<li>APO-ARIPiprazole;</li>
<li>Auro-ARIPiprazole;</li>
<li>MINT-Aripiprazole;</li>
<li>PMS-ARIPiprazole;</li>
<li>RIVA-ARIPiprazole;</li>
<li>SANDOZ ARIPiprazole;</li>
<li>TEVA-ARIPiprazole [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F999002"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Second Generation (Atypical) Antipsychotic </span></li></ul></div>
<div class="block dop drugH1Div" id="F3362491"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Oral solution may be substituted for the oral tablet on a milligram-per-milligram basis, up to 25 mg (eg, patients receiving 30 mg tablets should be given 25 mg oral solution). Orally disintegrating tablets (Abilify Discmelt) are bioequivalent to the IR tablets (Abilify).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="db52db42-feec-4cd0-8260-35fe729dcdb3">Bipolar I disorder; acute mania or episodes with mixed features</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar I disorder; acute mania or episodes with mixed features:</b>
<b>Note</b>
<b>:</b> Due to decreased risk of extrapyramidal symptoms, second-generation antipsychotics including aripiprazole have replaced first-generation antipsychotics for treatment as monotherapy or in combination with other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17195735','lexi-content-ref-29536616','lexi-content-ref-26237252','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17195735','lexi-content-ref-29536616','lexi-content-ref-26237252','lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents &lt;18 years: Oral: Initial: 2 mg once daily for 2 days, followed by 5 mg once daily for 2 days with a further increase to target dose of 10 mg once daily; subsequent dose increases may be made in 5 mg increments, up to a maximum daily dose: 30 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7887724-9f14-4457-844c-0c3849527fa5">Conduct disorder; aggression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Conduct disorder (CD); aggression:</b> Limited data available: Children ≥6 years and Adolescents: Oral: Initial: 1 to 2.5 mg once daily; may titrate at weekly intervals in 2.5 mg/day increments to clinical effectiveness; maximum daily dose: 15 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on two open-label, prospective studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21993869','lexi-content-ref-19702495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21993869','lexi-content-ref-19702495'])">Ref</a></span>) (n=43; age: 6 to 17 years) which evaluated pharmacokinetics and effectiveness in patients with a primary diagnosis of CD (with or without comorbid attention-deficit/hyperactivity disorder); results showed improvement in CD symptom scores with only minor improvements in cognition.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b7af6873-9ec0-4299-bc10-6258e1dfdb6d">Irritability, associated with autistic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritability, associated with autistic disorder:</b> Children ≥6 years and Adolescents &lt;18 years: Oral: Initial: 2 mg once daily for 7 days, followed by 5 mg once daily; subsequent dose increases may be made in 5 mg increments every ≥7 days, up to a maximum daily dose: 15 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia:</b>
<b>Note</b>
<b>:</b> Second-generation antipsychotics (including aripiprazole) are generally the preferred initial treatment in management of pediatric patients with schizophrenia due to decreased risk of extrapyramidal symptoms and tardive dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23972700','lexi-content-ref-26065063','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23972700','lexi-content-ref-26065063','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents 13 to &lt;18 years: Oral: Initial: 2 mg once daily for 2 days, followed by 5 mg once daily for 2 days with a further increase to target dose of 10 mg once daily; subsequent dose increases may be made in 5 mg increments up to a maximum daily dose: 30 mg/<b>day</b>. <b>Note:</b> A daily dose of 30 mg/day was <b>not</b> found to be more effective than the 10 mg/day dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="308cbb9f-ebfb-4bbc-90ee-cd1c4f6c900c">Tourette syndrome, tic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tourette syndrome, tic disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &lt;50 kg: Oral: Initial: 2 mg once daily for 2 days, then increase to target dose of 5 mg/day; in patients not achieving optimal control, dose may be further titrated at weekly intervals up to 10 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≥50 kg: Oral: Initial: 2 mg once daily for 2 days, then increase to 5 mg/day for 5 days, then increase to target dose of 10 mg/day on day 8 of therapy; in patients not achieving optimal control, dose may be further titrated at weekly intervals in 5 mg/day increments up to 20 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation</b>
<b> of therapy:</b> Children and Adolescents: American Academy of Child and Adolescent Psychiatry (AACAP), American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), National Institute for Health and Care Excellence (NICE), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451'])">Ref</a></span>); risk for withdrawal symptoms may be highest with highly anticholinergic or dopaminergic antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months and the APA guidelines recommend reducing the dose by 10% each month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-16529334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-16529334'])">Ref</a></span>). Continuing antiparkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When switching antipsychotics, three strategies have been suggested: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited and results are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064914"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥6 years and Adolescents: Oral: No dosage adjustment required.</p></div>
<div class="block dohp drugH1Div" id="F51064915"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥6 years and Adolescents: Oral: No dosage adjustment required.</p></div>
<div class="block doa drugH1Div" id="F136805"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8786" href="/d/html/8786.html" rel="external">see "Aripiprazole (oral and long-acting injectable [Abilify Maintena]): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> All doses are expressed as the equivalent amounts of aripiprazole (base).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Available formulations include oral tablets and oral solution supplied as aripiprazole (base) and 2 ER formulations available for IM administration: aripiprazole <b>monohydrate</b> (Abilify Maintena and Abilify Asimtufii) and aripiprazole <b>lauroxil</b> (Aristada and Aristada Initio); formulations and product brands vary in dose strength and frequency of administration (see Aripiprazole <b>Lauroxil </b>monograph).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21dde351-f095-4a55-8b49-bf5298b1e8e6">Agitation/Aggression associated with psychiatric disorders, substance intoxication, or other organic causes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/Aggression (acute, severe)</b>
<b>associated with psychiatric disorders (eg, schizophrenia, bipolar disorder), substance intoxication, or other organic causes (alternative agent) (off-label use)</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Antipsychotics are appropriate when psychosis is suspected to be the primary cause of agitation/aggression. Other agents are used preferentially in some intoxications (eg, stimulants) or alcohol withdrawal. Depending on presentation, may combine with a benzodiazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moore.2019','lexi-content-ref-22834451','lexi-content-ref-22461918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moore.2019','lexi-content-ref-22834451','lexi-content-ref-22461918'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 10 to 15 mg; may repeat based on response and tolerability every 2 hours up to 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moore.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moore.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b86ae9af-0983-405b-8c0b-a20590d54c4c">Agitation/Aggression and psychosis associated with dementia, severe or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/Aggression and psychosis associated with dementia, severe or refractory (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For short-term adjunctive use while addressing underlying causes of severe symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2 to 5 mg once daily; may increase dose based on response and tolerability in 5 mg increments at intervals ≥1 week up to 15 mg once daily. In patients without a clinically significant response after an adequate trial (eg, up to 4 weeks), taper and withdraw therapy. Only continue in patients with a demonstrated benefit and attempt to taper and withdraw at regular intervals; first taper attempt should occur ≤4 months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416','lexi-content-ref-16160622','lexi-content-ref-17974864','lexi-content-ref-18591574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416','lexi-content-ref-16160622','lexi-content-ref-17974864','lexi-content-ref-18591574'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Patients with dementia with Lewy bodies are at increased risk for severe adverse reactions; caution is required even with low doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1969751f-c027-4072-874e-d4df29195cbe">Bipolar disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Acute mania or episodes with mixed features (labeled use), acute hypomania (off-label use), and maintenance treatment (labeled use, formulation specific) as monotherapy or adjunctive therapy: Initial: 10 to 15 mg once daily; may increase dose based on response and tolerability in 5 to 10 mg/day increments at intervals of ≥1 week up to a maximum of 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23237061','lexi-content-ref-Stovall.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23237061','lexi-content-ref-Stovall.2019'])">Ref</a></span>). <b>Note:</b> Some experts suggest higher initial doses of up to 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stovall.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stovall.2019'])">Ref</a></span>). Although the manufacturer's labeling recommends waiting ≥2 weeks before increasing dose due to long half-life of aripiprazole, it may be appropriate to increase dose at 1 week for some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19407731','lexi-content-ref-26963842','lexi-content-ref-26338693','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19407731','lexi-content-ref-26963842','lexi-content-ref-26338693','lexi-content-ref-Manu.1'])">Ref</a></span>). For maintenance treatment, continue dose and combination regimen that was used to achieve control of the acute episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23237061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23237061'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, ER injectable suspension (aripiprazole monohydrate) (alternative agent): Note:</b> Establish tolerability with oral aripiprazole prior to initiation of ER injection; due to the prolonged half-life of oral aripiprazole, it may take up to 2 weeks to fully assess tolerability.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly injection (Abilify Maintena):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Single injection start:</b>
<b>IM: </b>400 mg once monthly (doses should be separated by ≥26 days). Continue (overlap) oral aripiprazole or other oral antipsychotic for 14 days during initiation of the ER injection.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Double injection start: IM: </b>Initial: Administer a single oral aripiprazole 20 mg dose, plus two 400 mg injections in separate injection sites (eg, right deltoid and left gluteal muscle). Maintenance: 400 mg once monthly (doses should be separated by ≥ 26 days) (Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage adjustment of monthly ER injection for adverse effects:</i> Consider reducing dose to 300 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Missed doses of monthly ER injection:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Second or third doses missed:</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;4 weeks but &lt;5 weeks since last dose: Administer next dose as soon as possible.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;5 weeks since last dose: Administer oral aripiprazole for 14 days with next injection <b>or </b>administer 1 oral aripiprazole dose of 20 mg plus <b>2</b> aripiprazole 400 mg IM injections in separate injection sites (eg, right deltoid and left gluteal muscle) (Canadian product monograph); adjust oral dose as needed based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:10em;">Fourth or subsequent doses missed:</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;4 weeks but &lt;6 weeks since last dose: Administer next dose as soon as possible.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;6 weeks since last dose: Administer oral aripiprazole for 14 days with next injection <b>or</b> administer 1 oral aripiprazole dose of 20 mg plus <b>2 </b>aripiprazole 400 mg IM injections in separate injection sites (eg, right deltoid and left gluteal muscle) (Canadian product monograph); adjust oral dose as needed based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Every-2-months injection (Abilify Asimtufii):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IM: </b>960 mg once every 2 months (56 days); may be given up to 2 weeks before or 2 weeks after the 2-month schedule timepoint. Continue (overlap) oral aripiprazole or other oral antipsychotic for 14 days during initiation of every-2-months ER injection. When converting from monthly injection (Abilify Maintena), administer every-2-months injection in place of the next monthly injection.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage adjustment of every-2-months ER injection for adverse effects:</i> Consider reducing dose to 720 mg every 2 months.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Missed doses of every-2-months ER injection:</i></p>
<p style="text-indent:-2em;margin-left:10em;">&gt;8 weeks and &lt;14 weeks since last dose: Administer next dose as soon as possible then resume the once every-2-months schedule.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;14 weeks since last dose: Administer oral aripiprazole for 14 days with next injection.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7092ebe4-ac53-4e80-904b-300a26f7a775">Delusional disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delusional disorder (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Dosing based on expert opinion:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2 to 5 mg once daily; gradually increase to 10 mg/day; if needed, may further increase dose at intervals of ≥1 week based upon response and tolerability up to 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manschreck.2019','lexi-content-ref-18588606','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manschreck.2019','lexi-content-ref-18588606','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7834615-81b5-448d-be0f-b6021963e20a">Delusional infestation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delusional infestation (delusional parasitosis) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosing based on expert opinion:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2 mg once daily; may increase dose gradually based on response and tolerability in 2 mg increments at intervals ≥2 weeks up to 12 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30543832','lexi-content-ref-23789596','lexi-content-ref-Suh.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30543832','lexi-content-ref-23789596','lexi-content-ref-Suh.2019'])">Ref</a></span>). Some patients may require doses up to 30 mg/day for optimal response. After achieving adequate response, maintain for ≥1 to 3 months before attempting to taper and discontinue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23789596','lexi-content-ref-Suh.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23789596','lexi-content-ref-Suh.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3090bfa5-98c5-40c3-aa49-de5e8ac1b63f">Huntington disease–associated chorea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Huntington disease–associated chorea (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2 mg once daily; may increase dose gradually based on response and tolerability up to a usual range of 7.5 to 15 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19170197','lexi-content-ref-19557093','lexi-content-ref-Suchowersky.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19170197','lexi-content-ref-19557093','lexi-content-ref-Suchowersky.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ce6216e-9365-4809-a16e-1401633c5309">Major depressive disorder, treatment resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar), treatment resistant (adjunctive therapy with antidepressant): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2 to 5 mg/day; may increase dose based on response and tolerability in 5 mg increments at intervals ≥1 week up to a manufacturer's maximum of 15 mg/day. A further increase up to 20 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19407731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19407731'])">Ref</a></span>). Although the manufacturer's labeling recommends waiting ≥2 weeks before increasing dose due to long half-life of aripiprazole, it may be appropriate to increase dose at 1 week for some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19407731','lexi-content-ref-26963842','lexi-content-ref-26338693','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19407731','lexi-content-ref-26963842','lexi-content-ref-26338693','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59e68a42-338e-45a3-bae2-8825f8f2f70d">Obsessive-compulsive disorder, treatment resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b> Obsessive-compulsive disorder, treatment resistant (adjunctive therapy to antidepressants) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 mg once daily; may increase dose gradually based on response and tolerability in 5 mg increments at intervals ≥1 week up to 15 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21437763','lexi-content-ref-APA.1','lexi-content-ref-21346614','lexi-content-ref-19629012','lexi-content-ref-22933237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21437763','lexi-content-ref-APA.1','lexi-content-ref-21346614','lexi-content-ref-19629012','lexi-content-ref-22933237'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 15 mg once daily; may increase dose based on response and tolerability in 5 mg increments at an interval of ≥4 days with initial low dose (eg, 5 mg) and at intervals ≥1 week thereafter up to a maximum of 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26963842','lexi-content-ref-19323965','lexi-content-ref-24385408','lexi-content-ref-26338693','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26963842','lexi-content-ref-19323965','lexi-content-ref-24385408','lexi-content-ref-26338693','lexi-content-ref-Manu.1'])">Ref</a></span>). Although the manufacturer's labeling recommends waiting ≥2 weeks before increasing dose due to long half-life of aripiprazole, it may be appropriate to increase dose at 1 week for some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19407731','lexi-content-ref-26963842','lexi-content-ref-26338693','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19407731','lexi-content-ref-26963842','lexi-content-ref-26338693','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, ER injectable suspension (aripiprazole monohydrate): Note:</b> Establish tolerability with oral aripiprazole prior to initiation of the ER injection; due to the prolonged half-life of oral aripiprazole, it may take up to 2 weeks to fully assess tolerability.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Monthly injection (Abilify Maintena):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Single injection start: <b>IM</b>: </b>400 mg once monthly (doses should be separated by ≥26 days). Continue (overlap) oral aripiprazole or other oral antipsychotic for 14 days during initiation of the ER injection.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Double injection start: <b>IM</b>: </b>Initial: Administer a single oral aripiprazole 20 mg dose, plus two 400 mg injections in separate injection sites (eg, right deltoid and left gluteal muscle). Maintenance: 400 mg once monthly (doses should be separated by ≥26 days) (Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage adjustment of monthly ER injection for adverse effects:</i> Consider reducing dose to 300 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Missed doses of monthly ER injection:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Second or third doses missed:</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;4 weeks but &lt;5 weeks since last dose: Administer next dose as soon as possible.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;5 weeks since last dose: Administer oral aripiprazole for 14 days with next injection <b>or </b>administer 1 oral aripiprazole dose of 20 mg plus <b>2 </b>aripiprazole 400 mg IM injections in separate injection sites (eg, right deltoid and left gluteal muscle) (Canadian product monograph); adjust oral dose as needed based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:10em;">Fourth or subsequent doses missed:</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;4 weeks but &lt;6 weeks since last dose: Administer next dose as soon as possible.</p>
<p style="text-indent:-2em;margin-left:12em;">&gt;6 weeks since last dose: Administer oral aripiprazole for 14 days with next injection<b> or </b>[Canadian dosing] administer 1 oral aripiprazole dose of 20 mg plus <b>2</b> aripiprazole 400 mg IM injections in separate injection sites (eg, right deltoid and left gluteal muscle) (Canadian product monograph); adjust oral dose as needed based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Every-2-months injection (Abilify Asimtuifii):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IM: </b>960 mg once every 2 months (56 days); may be given up to 2 weeks before or 2 weeks after the 2-month schedule timepoint. Continue (overlap) oral aripiprazole or other oral antipsychotic for 14 days during initiation of every-2-months ER injection. When converting from monthly injection (Abilify Maintena), administer every-2-months injection in place of the next monthly injection.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage adjustment of every-2-months ER injection for adverse effects:</i> Consider reducing dose to 720 mg every 2 months.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Missed doses of every-2-months ER injection:</i></p>
<p style="text-indent:-2em;margin-left:10em;">&gt;8 weeks and &lt;14 weeks since last dose: Administer next dose as soon as possible then resume the once every-2-months schedule.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;14 weeks since last dose: Administer oral aripiprazole for 14 days with next injection.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a7091d9-ef74-473f-960b-d3674a3d18df">Tourette syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tourette syndrome (off-label use): Oral:</b> Initial: 2.5 mg once daily; may increase dose based on response and tolerability in 2.5 mg increments at intervals ≥3 days up to 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27672358','lexi-content-ref-34757514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27672358','lexi-content-ref-34757514'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing conversions:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Orally disintegrating tablets to oral tablet:</b> Orally disintegrating tablets may be substituted for the oral tablet on a mg-per-mg basis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral solution to oral tablet:</b> Oral solution may be substituted for the oral tablet on a mg-per-mg basis, up to 25 mg. Patients receiving 30 mg tablets should be given 25 mg oral solution.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment based on CYP2D6 metabolizer status:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Aripiprazole dose should be reduced to 50% of the usual dose in known CYP2D6 poor metabolizers; subsequently adjust dose for favorable response and tolerability.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, ER injectable suspension (aripiprazole monohydrate):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Monthly injection (Abilify Maintena):</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Single injection start:</b> Reduce aripiprazole dose to 300 mg once monthly in known CYP2D6 poor metabolizers; subsequently adjust dose according to response and tolerability.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Double injection start:</b> Reduce initial 2 aripiprazole doses to 300 mg each and reduce monthly aripiprazole dose to 300 mg once monthly in known CYP2D6 poor metabolizers; subsequently adjust dose according to response and tolerability (Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Every-2-months injection (Abilify Asimtufii): </i>Reduce aripiprazole dose to 720 mg every 2 months in known CYP2D6 poor metabolizers.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral: </i>In the treatment of chronic psychiatric disease switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, gradual dose reduction (ie, over several weeks to months) is advised to detect a re-emergence of symptoms and to avoid withdrawal reactions (eg, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Long-acting injection:</i> Switching to other treatments is generally advised if side effects are intolerable or treatment is not effective. However, if a patient insists on stopping treatment, gradual dose reduction to avoid withdrawal reactions is generally <b>not</b> needed with long-acting injectable antipsychotics. The risk of withdrawal symptoms from discontinuation of long-acting injectables is low because the rate of drug elimination is slow. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-23343447','lexi-content-ref-Steinman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-23343447','lexi-content-ref-Steinman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Switching antipsychotics:</b> An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008'])">Ref</a></span>). Based upon clinical experience, some experts generally prefer cross-titration and overlap approaches rather than abrupt change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.2019'])">Ref</a></span>).</p></div>
<div class="block dora drugH1Div" id="F50991530"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18611062','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18611062','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound; large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound; large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988915"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block arsc drugH1Div" id="F54986976"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Activating/sedating effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Both activating effects (eg, <b>akathisia, restlessness</b>) and sedating effects (eg, <b>sedated state</b>, <b>drowsiness</b>) may occur with aripiprazole and may lead to nonadherence or discontinuation. Individual patient experience can vary depending on the person's sensitivity toward activation or sedation and the dose used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27093218','lexi-content-ref-28141623','lexi-content-ref-18533766','lexi-content-ref-23810019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27093218','lexi-content-ref-28141623','lexi-content-ref-18533766','lexi-content-ref-23810019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; sedation is believed to be due to H<sub>1</sub> antagonism leading to potential CNS depressant effects; aripiprazole is considered to display modest antagonism at H<sub>1</sub> receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26508859','lexi-content-ref-28291979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26508859','lexi-content-ref-28291979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Young age (in general, children and adolescents appear to be at higher risk for sedation due to antipsychotics compared to adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18533766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18533766'])">Ref</a></span>); in studies that included aripiprazole in children and adolescents, younger age has been associated with activating symptoms and higher age has been associated with sedating symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27093218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27093218'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic (aripiprazole is generally considered to be minimally sedating at usual therapeutic doses in comparison with other antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30192094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30192094'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dyslipidemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics are associated with dyslipidemia in adult and pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class. Aripiprazole is associated with a low risk of causing lipid abnormalities; however, <b>hypertriglyceridemia </b>and <b>hypercholesterolemia </b>have been observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30888439','lexi-content-ref-22234928','lexi-content-ref-19861668','lexi-content-ref-22009159','lexi-content-ref-Morrato.2012','lexi-content-ref-20187598','lexi-content-ref-17012695','lexi-content-ref-26218604','lexi-content-ref-27828697','lexi-content-ref-29075885','lexi-content-ref-30700975']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30888439','lexi-content-ref-22234928','lexi-content-ref-19861668','lexi-content-ref-22009159','lexi-content-ref-Morrato.2012','lexi-content-ref-20187598','lexi-content-ref-17012695','lexi-content-ref-26218604','lexi-content-ref-27828697','lexi-content-ref-29075885','lexi-content-ref-30700975'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; metabolic alterations from antipsychotics can develop in as short as 3 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747245','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747245','lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication use) is associated with a higher rate of morbidity/mortality compared to the general population, primarily due to cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151456'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Clozapine and olanzapine are associated with a high risk of hyperlipidemia while aripiprazole and ziprasidone are associated with the lowest risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24666104','lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24666104','lexi-content-ref-22009159'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extrapyramidal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Aripiprazole may cause extrapyramidal symptoms (EPS), also known as drug-induced movement disorders, particularly <b>akathisia</b> in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32246399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32246399'])">Ref</a></span>). Antipsychotics can cause 4 main EPS: Drug-induced <b>parkinsonism</b>, akathisia, acute <b>dystonia</b>, and <b>tardive dyskinesia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30949057','lexi-content-ref-21655344','lexi-content-ref-27395403','lexi-content-ref-27580493','lexi-content-ref-29924506','lexi-content-ref-20008446','lexi-content-ref-26509095','lexi-content-ref-29128325','lexi-content-ref-28045840','lexi-content-ref-24101361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30949057','lexi-content-ref-21655344','lexi-content-ref-27395403','lexi-content-ref-27580493','lexi-content-ref-29924506','lexi-content-ref-20008446','lexi-content-ref-26509095','lexi-content-ref-29128325','lexi-content-ref-28045840','lexi-content-ref-24101361'])">Ref</a></span>). EPS presenting as <b>dysphagia</b>, <b>esophageal motility disorder</b>, or <b>pulmonary aspiration</b> have also been reported with antipsychotics, which may not be recognized as EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499','lexi-content-ref-21541978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499','lexi-content-ref-21541978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> EPS: Dose-related; due to antagonism of dopaminergic D<sub>2</sub> receptors in nigrostriatal pathways (as either antagonists or as a partial agonist, such as aripiprazole) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10686232','lexi-content-ref-31067549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10686232','lexi-content-ref-31067549'])">Ref</a></span>). Akathisia: Mechanism not completely understood, but possibly associated with the low activity of dopaminergic projections from the midbrain to the ventral striatum and imbalance between the dopamine and serotonin neurotransmitter system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22234928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22234928'])">Ref</a></span>). Tardive dyskinesia: Time-related (delayed); results from chronic exposure to dopamine 2 receptor antagonists leading to up-regulation of these receptors over time; aripiprazole has partial agonistic activity at the D<sub>2</sub> receptor; however, it has one of the highest D<sub>2</sub> receptor affinities among the antipsychotic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30949057','lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30949057','lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Acute dystonia</span>: Rapid; in the majority of cases, dystonia usually occurs within the first 5 days after initiating antipsychotic therapy (and even with the first dose, particularly in patients receiving parenteral antipsychotics) or a dosage increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Drug-induced parkinsonism</span>: Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within 1 month and 90% within 3 months of antipsychotic initiation, a dosage increase, or a change in the medication regimen (such as adding another antipsychotic agent or discontinuing an anticholinergic medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Akathisia</span>: Varied; may begin within several days after antipsychotic initiation but usually increases with treatment duration, occurring within 1 month in up to 50% of cases and within 3 months in 90% of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Tardive dyskinesia</span>: Delayed; symptoms usually appear after 1 to 2 years of continuous exposure to a dopamine 2 receptor antagonist, and almost never before 3 months, with an insidious onset, evolving into a full syndrome over days and weeks, followed by symptom stabilization and then a chronic waxing and waning of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Esophageal dysfunction (associated with EPS)</span>: Varied; ranges from weeks to months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14565800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14565800'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">EPS (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior history of EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Younger age (in general, children and adolescents are usually at higher risk for EPS compared to adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18533766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18533766'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Aripiprazole is usually associated with a lower risk of EPS, with the possible exception of akathisia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-29924506','lexi-content-ref-32246399','lexi-content-ref-26509095','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-29924506','lexi-content-ref-32246399','lexi-content-ref-26509095','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Acute dystonia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Young age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced parkinsonism:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Akathisia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Mood disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Tardive dyskinesia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;55 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Cognitive impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant treatment with anticholinergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diagnosis of schizophrenia or affective disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31325958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31325958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Greater total antipsychotic exposure (especially first-generation antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of extrapyramidal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance misuse or dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Race (White or African descent). <b>Note:</b> Although early literature supported race as a potential risk factor for tardive dyskinesia (Morgenstern 1993), newer studies have challenged this assertion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28146614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28146614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Esophageal dysfunction (associated with EPS):</p>
<p style="text-indent:-2em;margin-left:8em;">• Certain comorbidities such as neurologic degenerative disease, dementia, stroke, Parkinson disease, or myasthenia gravis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults &gt;75 years of age (may be risk factor due to age related muscle atrophy, cognitive impairment, reduced esophageal peristalsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukopenia </b>and <b>neutropenia </b>have been reported with aripiprazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29715374','lexi-content-ref-21058927','lexi-content-ref-29034139','lexi-content-ref-19287562','lexi-content-ref-32448188']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29715374','lexi-content-ref-21058927','lexi-content-ref-29034139','lexi-content-ref-19287562','lexi-content-ref-32448188'])">Ref</a></span>). <b>Agranulocytosis</b> has been reported with other atypical antipsychotics and, per the manufacturer's labeling, has also been reported with aripiprazole.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; likely idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29034139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29034139'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, drug-induced neutropenia usually manifests after 1 or 2 weeks of exposure and agranulocytosis usually appears 3 to 4 weeks following initiation of therapy; however, the onset may be insidious (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of drug-induced leukopenia/neutropenia and preexisting low white blood cell count/absolute neutrophil count</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics are associated with <b>hyperglycemia</b>, to varying degrees, which is a component of the metabolic syndrome observed with this pharmacologic class. Aripiprazole is associated with a low risk of causing metabolic alterations; however, glycemic abnormalities ranging from mild<b> insulin resistance</b> or hyperglycemia to new-onset <b>diabetes mellitus, diabetes mellitus with hyperosmolar coma</b>, and <b>diabetic ketoacidosis</b>, including fatal cases, have been observed very rarely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18468728','lexi-content-ref-24666104','lexi-content-ref-18752391','lexi-content-ref-19192469','lexi-content-ref-26218604','lexi-content-ref-23835329','lexi-content-ref-18348593','lexi-content-ref-24446539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18468728','lexi-content-ref-24666104','lexi-content-ref-18752391','lexi-content-ref-19192469','lexi-content-ref-26218604','lexi-content-ref-23835329','lexi-content-ref-18348593','lexi-content-ref-24446539'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; new-onset diabetes has been observed within first 3 months to a median onset of 3.9 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20520598','lexi-content-ref-18348593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20520598','lexi-content-ref-18348593'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• African American race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &lt;35 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting obesity, poor exercise habits, or other risk factors for diabetes, including family history of diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Exposure to other agents that also increase the risk of hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Type 2 diabetes mellitus: Extended exposure (mean: 17.2 months) in pediatric patients 10 to 18 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25844991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25844991'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Metabolic disturbances appear to be the greatest with clozapine and olanzapine and lowest with aripiprazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Impulse control disorders</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Aripiprazole has been associated with an increased risk of developing <b>impulse control disorders</b>, which primarily manifests as <b>pathological gambling</b>, although other reported behaviors include hypersexuality, compulsive buying, compulsive eating, and/or other intense urges (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28102975','lexi-content-ref-24315783','lexi-content-ref-25329919','lexi-content-ref-28696131','lexi-content-ref-20180730']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28102975','lexi-content-ref-24315783','lexi-content-ref-25329919','lexi-content-ref-28696131','lexi-content-ref-20180730'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; may be due to aripiprazole’s partial dopamine agonist activity in brain circuits regulating reward pathways such as the mesolimbic circuitry (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28102975','lexi-content-ref-30849063','lexi-content-ref-28696131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28102975','lexi-content-ref-30849063','lexi-content-ref-28696131'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; case reports and case series of aripiprazole-associated pathological gambling suggest that the onset occurs between a few days and a few months after initiation, with some cases occurring only after an increase in dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24315783','lexi-content-ref-30849063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24315783','lexi-content-ref-30849063'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of impulse control disorders and gambling behaviors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24315783','lexi-content-ref-30849063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24315783','lexi-content-ref-30849063'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• The depot formulation (aripiprazole lauroxil) may be associated with an increased risk compared to oral aripiprazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28777129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28777129'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality in older adults</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Older adults with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20053539','lexi-content-ref-15845964','lexi-content-ref-30042077','lexi-content-ref-31433335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20053539','lexi-content-ref-15845964','lexi-content-ref-30042077','lexi-content-ref-31433335'])">Ref</a></span>). In addition, an increased incidence of cerebrovascular effects (eg, <b>cerebrovascular accident, transient ischemic attacks</b>), including fatalities, have been reported in placebo-controlled aripiprazole trials in older adults with dementia-related psychosis, per the manufacturer's labeling. Of note, aripiprazole is not approved for the treatment of dementia-related psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; possible mechanisms include arrhythmia, cardiac arrest, and extrapyramidal effects that may increase the risk of falls, aspirations, and pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24016844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24016844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25140533','lexi-content-ref-22193526','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25140533','lexi-content-ref-22193526','lexi-content-ref-25786075'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dementia-related psychosis (eg, Lewy body dementia, Parkinson disease dementia)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuroleptic malignant syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">All antipsychotics have been associated with <b>neuroleptic malignant syndrome </b>(NMS), although the incidence is less with second-generation (atypical) antipsychotics compared to first-generation (typical) antipsychotics. There are case reports of NMS with aripiprazole, including monotherapy. Some data suggest that NMS induced by certain second-generation antipsychotics, including aripiprazole, may present with milder or atypical features more frequently compared to NMS induced by other agents; these atypical features include less intense extrapyramidal symptoms or less extreme fever (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30730330','lexi-content-ref-30375086','lexi-content-ref-25578944','lexi-content-ref-17414689','lexi-content-ref-17272970','lexi-content-ref-20651315','lexi-content-ref-15564813','lexi-content-ref-28045840','lexi-content-ref-18628446','lexi-content-ref-22626633','lexi-content-ref-25838319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30730330','lexi-content-ref-30375086','lexi-content-ref-25578944','lexi-content-ref-17414689','lexi-content-ref-17272970','lexi-content-ref-20651315','lexi-content-ref-15564813','lexi-content-ref-28045840','lexi-content-ref-18628446','lexi-content-ref-22626633','lexi-content-ref-25838319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; idiosyncratic. Believed to be due to a reduction in CNS dopaminergic tone, along with the dysregulation of autonomic nervous system activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25578944','lexi-content-ref-17414689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25578944','lexi-content-ref-17414689'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, most patients develop NMS within 2 weeks of initiating an antipsychotic, and in some patients, prodromal symptoms emerge within hours of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17414689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17414689'])">Ref</a></span>). However, there are many cases of NMS occurring months after stable therapy, including a report of NMS developing 1 year after treatment with aripiprazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30730330','lexi-content-ref-12766935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30730330','lexi-content-ref-12766935'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (twice as likely to develop NMS compared to females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9735957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9735957'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• High-dose antipsychotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant lithium or benzodiazepine (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Catatonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Pharmacokinetic interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Intramuscular administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dosage escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychomotor agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics have been associated with <b>sexual disorder</b> in both males and females. Antipsychotic treatment has been associated with effects on all phases of sexual activity (libido, arousal, and orgasm); however, many patients with schizophrenia experience more frequent sexual dysfunction, with or without antipsychotic treatment. Conversely, there are also case reports of hypersexuality<b>
<i>,</i></b>related to impulse control disorders, occurring with use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28033456','lexi-content-ref-23737244','lexi-content-ref-20187598','lexi-content-ref-21720229','lexi-content-ref-29107566','lexi-content-ref-21191308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28033456','lexi-content-ref-23737244','lexi-content-ref-20187598','lexi-content-ref-21720229','lexi-content-ref-29107566','lexi-content-ref-21191308'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Antipsychotic-induced sexual dysfunction has been attributed to many potential mechanisms, including dopamine receptor antagonism, dopamine D<sub>2 </sub>receptor antagonism in the hypothalamic infundibular system causing hyperprolactinemia, histamine receptor antagonism, cholinergic receptor antagonism, and alpha-adrenergic receptor antagonism. Of note, in adults, aripiprazole is associated with a minimal risk of causing hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Hyperprolactinemia (although a correlation with sexual dysfunction has been observed, a relationship has not been confirmed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (the prevalence of antipsychotic-induced sexual dysfunction in patients with schizophrenia is high [~50% to 60% compared with 31% of males in the general population]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22533871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22533871'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Aripiprazole is associated with lower rates of sexual dysfunction relative to other antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244','lexi-content-ref-21191308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244','lexi-content-ref-21191308'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Temperature dysregulation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics may impair the body's ability to regulate core body temperature, which may cause a potentially life-threatening heatstroke during predisposing conditions such as a heat wave or strenuous exercise. There are also several case reports of potentially life-threatening <b>hypothermia </b>associated with aripiprazole use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17698676','lexi-content-ref-30398998','lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17698676','lexi-content-ref-30398998','lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; idiosyncratic. Exact mechanism is unknown; however, body temperature is regulated by the hypothalamus with complex involvement of the dopamine, serotonin, and norepinephrine neurotransmitters. D<sub>2 </sub>antagonism may cause an increase in body temperature, while 5-HT<sub>2A</sub> (serotonin) receptor antagonism and 5-HT<sub>1</sub> receptor agonism may cause a decrease in body temperature. Aripiprazole is a partial agonist at D<sub>2</sub> receptors, an antagonist at 5-HT<sub>2A </sub>receptor, and a partial agonist at 5-HT<sub>1A</sub> receptor. In addition, antagonism of peripheral alpha-adrenergic receptors has also been suggested as a factor in the hypothermic effect, by inhibiting peripheral responses to cooling (vasoconstriction and shivering) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30398998','lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30398998','lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Hypothermia: Varied; antipsychotic-induced hypothermia cases indicate a typical onset in the period shortly after initiation of therapy or a dosage increase (first 7 to 10 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Heat stroke:</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychiatric illness (regardless of medication use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Strenuous exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Heat exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant medications possessing anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypothermia:</p>
<p style="text-indent:-2em;margin-left:8em;">• In general, predisposing risk factors include: Older adults, cerebrovascular accident, preexisting brain damage, hypothyroidism, malnutrition, shock, sepsis, adrenal insufficiency, diabetes, disability, burns, exfoliative dermatitis, benzodiazepine use, alcohol intoxication, kidney or liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24688758','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24688758','lexi-content-ref-28936184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia (regardless of antipsychotic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Aripiprazole may cause significant <b>weight gain </b>(increase of <span style="text-decoration: underline">&gt;</span>7% from baseline), particularly in pediatric patients, which is a component of the metabolic syndrome observed with this pharmacologic class (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31524318','lexi-content-ref-19861668','lexi-content-ref-15600384','lexi-content-ref-29905899','lexi-content-ref-29075885']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31524318','lexi-content-ref-19861668','lexi-content-ref-15600384','lexi-content-ref-29905899','lexi-content-ref-29075885'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Multiple proposed mechanisms, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects explained by differing affinity of antipsychotics at these receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-24424705','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-24424705','lexi-content-ref-26218604'])">Ref</a></span>). Aripiprazole displays a low affinity for histamine H<sub>1</sub> receptors, which may account for the relatively low risk of weight gain associated with aripiprazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21693430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21693430'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; antipsychotic-induced weight gain usually occurs rapidly in the initial period following initiation, then gradually decreases and flattens over several months with patients continuing to gain weight in the long term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-31509359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-31509359'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Parental BMI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19861668','lexi-content-ref-28883731','lexi-content-ref-15998156','lexi-content-ref-30672720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19861668','lexi-content-ref-28883731','lexi-content-ref-15998156','lexi-content-ref-30672720'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid weight gain in the initial period: Younger age, lower baseline BMI, more robust response to antipsychotic, and increase in appetite; rapid weight gain of &gt;5% in the first month has been observed as the best predictor for significant long-term weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication) is associated with a higher prevalence of obesity compared to the general population due to components of the illness such as negative symptoms, sedentary lifestyles, and unhealthy diets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861176'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: In adults, aripiprazole is considered to have a minimal or low risk for weight gain; clozapine and olanzapine are considered to have high propensity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24666104','lexi-content-ref-28883731','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24666104','lexi-content-ref-28883731','lexi-content-ref-20187598'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F136766"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults receiving monotherapy unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">IM:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Decreased HDL cholesterol (14%), increased LDL cholesterol (10% to 14%), increased serum cholesterol (4% to 22%), increased serum triglycerides (7% to 27%), weight gain (17% to 22%)<span class="lexi-table-link-container"> (<a aria-label="Weight Gain (IM) table link" class="lexi-table-link" data-table-id="lexi-content-weight-gain-im" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-gain-im')">table 1</a>)</span><span class="table-link" style="display:none;">Weight Gain (IM)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Gain (IM)" frame="border" id="lexi-content-weight-gain-im" rules="all">
<caption style="text-align:center;">
<b>Aripiprazole: Adverse Reaction: Weight Gain (IM)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">144</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">141</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% of body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">167</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">172</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% of body weight</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Akathisia (2% to 12%)<span class="lexi-table-link-container"> (<a aria-label="Akathisia (IM) table link" class="lexi-table-link" data-table-id="lexi-content-akathisia-im" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-akathisia-im')">table 2</a>)</span><span class="table-link" style="display:none;">Akathisia (IM)</span>, headache (12%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Akathisia (IM)" frame="border" id="lexi-content-akathisia-im" rules="all">
<caption style="text-align:center;">
<b>Aripiprazole: Adverse Reaction: Akathisia (IM)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Agitation associated with schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">220</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">167</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">172</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Orthostatic hypotension (≤3%), tachycardia (2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Increased serum glucose (8%), weight loss (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distress (2%), constipation (10%), diarrhea (3%), nausea (9%), vomiting (3%), xerostomia (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Neutropenia (6%)<span class="lexi-table-link-container"> (<a aria-label="Neutropenia (IM) table link" class="lexi-table-link" data-table-id="lexi-content-neutropenia-im" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-neutropenia-im')">table 3</a>)</span><span class="table-link" style="display:none;">Neutropenia (IM)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Neutropenia (IM)" frame="border" id="lexi-content-neutropenia-im" rules="all">
<caption style="text-align:center;">
<b>Aripiprazole: Adverse Reaction: Neutropenia (IM)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Local: Injection-site reaction (≥1%; including bleeding at injection site, bruising at injection site, erythema at injection site, induration at injection site, inflammation at injection site, injection-site pruritus, rash at injection site, swelling at injection), pain at injection site (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Anxiety (≥1%), dizziness (4% to 8%), drowsiness (7%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness (IM) table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness-im" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness-im')">table 4</a>)</span><span class="table-link" style="display:none;">Drowsiness (IM)</span>, extrapyramidal reaction (10%), fatigue (2%), insomnia (≥1%), sedated state (3% to 5%), restlessness (≥1%), tremor (3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness (IM)" frame="border" id="lexi-content-drowsiness-im" rules="all">
<caption style="text-align:center;">
<b>Aripiprazole: Adverse Reaction: Drowsiness (IM)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IM injection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Agitation associated with schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">501</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">220</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Arthralgia (4%), back pain (4%), dystonia (2%), musculoskeletal pain (3%), myalgia (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Nasal congestion (2%), upper respiratory tract infection (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Abnormal T waves on ECG, bradycardia, chest discomfort, decreased blood pressure, hypertension, orthostatic dizziness, presyncope, prolonged QT interval on ECG, sinus tachycardia, syncope</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Decreased serum cholesterol, decreased serum triglycerides, hyperinsulinism, hyperprolactinemia, increased libido, obesity</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Bruxism, decreased appetite, dysgeusia, dyspepsia, upper abdominal pain</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Delayed ejaculation, glycosuria, pollakiuria, urinary incontinence</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Abnormal hepatic function tests, hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Hypersensitivity reaction, swollen tongue</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Abnormal gait, aggressive behavior, agitation, hypersomnia, irritability, lethargy, memory impairment, panic attack, psychotic reaction, seizure, trismus</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Bradykinesia, dystonia (oromandibular), increased creatinine phosphokinase in blood specimen, joint stiffness, muscle twitching, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Blurred vision, oculogyric crisis</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Nasopharyngitis</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Increased serum glucose (children and adolescents: 3% to 5%; adults: 18%), weight gain (children and adolescents: 3% to 26%; adults: 2% to 8%)<span class="lexi-table-link-container"> (<a aria-label="Weight Gain (Oral) table link" class="lexi-table-link" data-table-id="lexi-content-weight-gain-oral" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-weight-gain-oral')">table 5</a>)</span><span class="table-link" style="display:none;">Weight Gain (Oral)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Weight Gain (Oral)" frame="border" id="lexi-content-weight-gain-oral" rules="all">
<caption style="text-align:center;">
<b>Aripiprazole: Adverse Reaction: Weight Gain (Oral)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Irritability associated with autistic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">209</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">98</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% of body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">381</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">187</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% of body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia, bipolar mania, autistic disorder, or Tourette disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">732</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Tourette disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">105</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">66</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% of body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">719</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">598</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% of body weight</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">852</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">379</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≥7% of body weight</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Constipation (children and adolescents: 2%; adults: 11%), nausea (children, adolescents, and adults: 8% to 15%), vomiting (children, adolescents, and adults: 8% to 14%)</p>
<p style="text-indent:-2em;margin-left:6em;">Local: Application-site rash (MyCite patch: 12%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Agitation (19%), akathisia (children, adolescents, and adults: 3% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Akathisia (Oral) table link" class="lexi-table-link" data-table-id="lexi-content-akathisia-oral" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-akathisia-oral')">table 6</a>)</span><span class="table-link" style="display:none;">Akathisia (Oral)</span>, anxiety (17%), drowsiness (children and adolescents: 10% to 26%; adults: 5% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness (Oral) table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness-oral" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness-oral')">table 7</a>)</span><span class="table-link" style="display:none;">Drowsiness (Oral)</span>, extrapyramidal reaction (children and adolescents: 6% to 27%; adults: 5% to 16%), fatigue (children and adolescents: 4% to 22%; adults: 6%), headache (children and adolescents: 10% to 12%; adults: 27%), insomnia (18%), sedated state (children and adolescents: 9% to 21%; adults: ≤13%), tremor (children, adolescents, and adults: 5% to 12%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Akathisia (Oral)" frame="border" id="lexi-content-akathisia-oral" rules="all">
<caption style="text-align:center;">
<b>Aripiprazole: Adverse Reaction: Akathisia (Oral)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Autistic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">197</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">97</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia, bipolar mania, autistic disorder, or Tourette disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">732</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Tourette disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">917</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">753</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,843</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,166</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness (Oral)" frame="border" id="lexi-content-drowsiness-oral" rules="all">
<caption style="text-align:center;">
<b>Aripiprazole: Adverse Reaction: Drowsiness (Oral)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Autistic disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">212</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">101</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">197</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">97</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia, bipolar mania, autistic disorder, or Tourette disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">732</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Tourette disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">72</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Including sedation</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Including sedation</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Including sedation</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Including sedation</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,843</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,166</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Orthostatic hypotension (children, adolescents, and adults: ≤4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Skin rash (children, adolescents, and adults: ≤2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Decreased HDL cholesterol (children and adolescents: 4%), increased serum cholesterol (children and adolescents: 1%), increased serum triglycerides (children, adolescents, and adults: 5% to 10%), weight loss (≥1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distress (children, adolescents, and adults: 2% to 3%), anorexia (≥1%), decreased appetite (children and adolescents: 5% to 7%), diarrhea (children and adolescents: 4%), dyspepsia (9%), increased appetite (children and adolescents: 7%), sialorrhea (children and adolescents: 4% to 8%), stomach discomfort (3%), upper abdominal pain (children and adolescents: 3%), xerostomia (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Urinary incontinence (≥1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia (children and adolescents: 2%; adults: ≥1%), dizziness (children, adolescents, and adults: 3% to 10%), drooling (children and adolescents: 3% to 9%), irritability (children and adolescents: 2%), lethargy (children and adolescents: 3% to 5%), pain (3%), restlessness (5% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Restlessness (Oral) table link" class="lexi-table-link" data-table-id="lexi-content-restlessness-oral" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-restlessness-oral')">table 8</a>)</span><span class="table-link" style="display:none;">Restlessness (Oral)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Restlessness (Oral)" frame="border" id="lexi-content-restlessness-oral" rules="all">
<caption style="text-align:center;">
<b>Aripiprazole: Adverse Reaction: Restlessness (Oral)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">917</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">753</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia or bipolar mania</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,843</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,166</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Dystonia (children and adolescents: 2%)<span class="lexi-table-link-container"> (<a aria-label="Dystonia (Oral) table link" class="lexi-table-link" data-table-id="lexi-content-dystonia-oral" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dystonia-oral')">table 9</a>)</span><span class="table-link" style="display:none;">Dystonia (Oral)</span>, limb pain (4%), muscle rigidity (children and adolescents: 2%), muscle spasm (2%), myalgia (2%), stiffness (children, adolescents, and adults: 2% to 4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dystonia (Oral)" frame="border" id="lexi-content-dystonia-oral" rules="all">
<caption style="text-align:center;">
<b>Aripiprazole: Adverse Reaction: Dystonia (Oral)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Aripiprazole)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Schizophrenia, bipolar mania, autistic disorder, or Tourette disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">732</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">370</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Blurred vision (children, adolescents, and adults: 3% to 8%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Cough (3%), epistaxis (children and adolescents: 2%), nasopharyngitis (children and adolescents: 6% to 9%), pharyngolaryngeal pain (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (children and adolescents: 4% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Acute cardiorespiratory failure, acute myocardial infarction, angina pectoris, atrial fibrillation, atrial flutter, atrioventricular block, bradycardia, chest pain, hypertension, hypotension, ischemic heart disease, orthostatic dizziness, palpitations, peripheral edema, prolonged QT interval on ECG, syncope</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Alopecia, hyperhidrosis, pruritus, skin photosensitivity, urticaria</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Amenorrhea, change in libido, elevated glycosylated hemoglobin, gynecomastia, hypoglycemia, hypokalemia, hyponatremia, increased lactate dehydrogenase, increased serum prolactin, menstrual disease</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Gastroesophageal reflux disease</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Anorgasmia, erectile dysfunction, mastalgia, nocturia, priapism, urinary retention</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Hepatitis, increased gamma-glutamyl transferase, increased liver enzymes, increased serum bilirubin, jaundice</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Facial edema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Aggressive behavior, akinesia, ataxia, catatonia, choreoathetosis, cogwheel rigidity, delirium, homicidal ideation, hypertonia, impaired mobility, memory impairment, myasthenia, myoclonus, parkinsonism, seizure, somnambulism, speech disturbance, tic disorder</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Bradykinesia, hypokinesia, increased creatinine phosphokinase in blood specimen, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Diplopia, photophobia</p>
<p style="text-indent:-2em;margin-left:6em;">Renal: Increased blood urea nitrogen</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Dyspnea, nasal congestion</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any route or population):</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hirsutism</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Esophageal motility disorder, tongue spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Sleep talking</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary aspiration</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any route or population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pericarditis (Onggo 2023), torsades de pointes (Nelson 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (new onset) (van Winkel 2008), diabetes mellitus with hyperosmolar coma (Campanella 2009), diabetic ketoacidosis (Church 2005, Makhzoumi 2008), hypercholesterolemia (Vazquez-Bourgon 2018), hyperglycemia (Church 2005, Stern 2012), hypertriglyceridemia (Vazquez-Bourgon 2018), insulin resistance (Teff 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysphagia (Lin 2012), hiccups (Carbone 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Sexual disorder (La Torre 2013, Serretti 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, leukopenia (Qureshi 2008), neutropenia (Felin 2018, Majeed 2017), transient neutropenia (pseudoneutropenia) (Pinnaka 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Shirk 2021), drug reaction with eosinophilia and systemic symptoms (Taleb 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, hypothermia (Szota 2019, Zonnenberg 2017), impulse control disorder (including compulsive buying, compulsive eating, hypersexuality, pathological gambling) (Bulbena-Cabré 2016; Dhillon 2017, Peterson 2017), neuroleptic malignant syndrome (Agrawal 2019, Palakurthi 2007), suicidal ideation (Padder 2006, Selvaraj 2010), suicidal tendencies (Meyer 2022), transient ischemic attacks</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tardive dyskinesia (Aguilar 2019, She 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hypersensitivity pneumonitis (Gunasekaran 2017), sleep apnea (obstructive) (Health Canada 2016; Kohen 2009; Shirani 2011)</p></div>
<div class="block coi drugH1Div" id="F136781"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylaxis, pruritus, urticaria) to aripiprazole or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F136764"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse reactions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiac disease, cerebrovascular disease, prior myocardial infarction, ischemic heart disease, or conditions that predispose to hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parkinson disease: Use with caution in patients with Parkinson disease; antipsychotics may aggravate motor disturbances (APA [Keepers 2020]; APA [Reus 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Tablets may contain lactose; avoid use in patients with galactose intolerance or glucose-galactose malabsorption.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Orally disintegrating tablets may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Injection: There are 2 ER aripiprazole formulations available for IM administration: aripiprazole <b>monohydrate</b> (Abilify Maintena and Abilify Asimtufii) and aripiprazole <b>lauroxil</b> (Aristada and Aristada Initio); formulations and product brands vary in dose strength and frequency of administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tablet with sensor: The ability of aripiprazole tablets with sensor to improve patient compliance or modify aripiprazole dosage has not been established. The use of aripiprazole tablets with sensor to track drug ingestion in “real time” or during an emergency is not recommended because detection may be delayed or not occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]). Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, insomnia, irritability, GI symptoms, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878335"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric psychiatric disorders are frequently serious disorders which present with variable symptoms that do not always match adult diagnostic criteria. Conduct a thorough diagnostic evaluation and carefully consider risks of psychotropic medication before initiation in pediatric patients with schizophrenia, bipolar disorder, irritability associated with autistic disorder, or Tourette disorder. Medication therapy for pediatric patients with these disorders is indicated as part of a total treatment program that frequently includes educational, psychological, and social interventions. Long-term usefulness of aripiprazole should be periodically re-evaluated in patients receiving the drug for extended periods of time.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block dosfc drugH1Div" id="F26641004"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Oral solution contains fructose 200 mg and sucrose 400 mg per mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Aripiprazole tablets are also available with an embedded device that tracks drug ingestion using a smartphone app (Abilify Mycite). Abilify MyCite is a drug-device combination product comprised of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor and packaged with a wearable sensor patch intended to track drug ingestion.</p>
<p style="text-indent:-2em;margin-left:4em;">Abilify MyCite Kit is packaged with seven 1-component patches (electronic recording component is contained in each patch).</p>
<p style="text-indent:-2em;margin-left:4em;">Abilify MyCite Starter Kit is packaged with 1 sensor pod and 7 adhesive patches (electronic recording component is contained in the pod).</p>
<p style="text-indent:-2em;margin-left:4em;">Abilify MyCite Maintenance Kit is packaged with 7 adhesive patches (for use with the sensor pod supplied separately).</p></div>
<div class="block foc drugH1Div" id="F136774"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Prefilled Syringe, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abilify Maintena: 300 mg (extended release) (1 ea); 400 mg (extended release) (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Prefilled Syringe, Intramuscular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abilify Asimtufii: 720 mg/2.4 mL (extended release) (2.4 mL); 960 mg/3.2 mL (extended release) (3.2 mL) [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (150 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted ER, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abilify Maintena: 300 mg (extended release) (1 ea); 400 mg (extended release) (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abilify: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg [contains corn starch, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abilify MyCite: 2 mg [DSC], 5 mg [DSC], 10 mg [DSC], 15 mg [DSC], 20 mg [DSC], 30 mg [DSC] [contains corn starch, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 15 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abilify MyCite Maintenance Kit: 2 mg (30 ea); 5 mg (30 ea); 10 mg (30 ea); 15 mg (30 ea); 20 mg (30 ea); 30 mg (30 ea) [contains corn starch, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abilify MyCite Starter Kit: 2 mg (30 ea); 5 mg (30 ea); 10 mg (30 ea); 15 mg (30 ea); 20 mg (30 ea); 30 mg (30 ea) [contains corn starch, fd&amp;c blue #2 (indigo carm) aluminum lake]</p></div>
<div class="block geq drugH1Div" id="F136761"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F136783"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe</b> (Abilify Asimtufii Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">720MG/2.4ML (per mL): $2,114.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">960MG/3.2ML (per mL): $2,114.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe</b> (Abilify Maintena Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2,537.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $3,383.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (ARIPiprazole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $2.08 - $7.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Reconstituted ER</b> (Abilify Maintena Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2,537.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $3,383.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Abilify MyCite Maintenance Kit Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Abilify MyCite Starter Kit Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $67.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (ARIPiprazole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $41.87 - $41.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $41.87 - $41.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Abilify Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $23.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $23.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $23.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $23.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $33.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $33.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (ARIPiprazole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.09 - $32.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.11 - $32.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.14 - $32.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.18 - $32.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.25 - $45.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.26 - $45.41</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865978"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted ER, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abilify Maintena: 300 mg (extended release) (1 ea); 400 mg (extended release) (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abilify: 2 mg, 5 mg [contains corn starch, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abilify: 10 mg, 15 mg, 20 mg, 30 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg</p></div>
<div class="block admp drugH1Div" id="F52612264"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer all dosage forms without regard to food.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Do not remove tablet from blister pack until ready to administer; do not push tablet through foil (tablet may become damaged); peel back foil to expose tablet; use dry hands to remove tablet and place immediately on tongue. Tablet dissolves rapidly in saliva and may be swallowed without liquid; if needed, tablet can be taken with liquid. Do not split tablet.</p></div>
<div class="block adm drugH1Div" id="F136778"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Extended release: For IM use only; do not administer SUBQ or IV.</p>
<p style="text-indent:-2em;margin-left:4em;">Monthly injection (Abilify Maintena): Inject slowly into deltoid or gluteal muscle using the appropriate provided needle; for nonobese patients, use the 1-inch (25 mm) needle with deltoid administration or the 1.5-inch (38 mm) needle with gluteal administration; for obese patients, use the 1.5-inch (38 mm) needle with deltoid administration or the 2-inch (51 mm) needle with gluteal administration. Do not massage muscle after administration. Rotate injection sites between the 2 deltoid or gluteal muscles. Administer monthly (doses should be separated by ≥26 days).</p>
<p style="text-indent:-2em;margin-left:4em;">Every-2-months injection (Abilify Asimtufii): Inject slowly into gluteal muscle using the appropriate provided needle; for nonobese patients, use the 22-gauge, 1.5-inch (38 mm) needle; for obese patients, use the 21-gauge, 2-inch (51 mm) needle. Do not massage muscle after administration. Administer every 2 months (doses should be separated by 56 days); may be given up to 2 weeks before or 2 weeks after the 2-month schedule timepoint.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Remove from foil blister by peeling back (do not push tablet through the foil). Place tablet in mouth immediately upon removal. Tablet dissolves rapidly in saliva and may be swallowed without liquid. If needed, can be taken with liquid. Do not split tablet.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet with sensor: Swallow tablets whole; do not divide, crush, or chew. Each tablet is embedded with an ingestible event marker (IEM). The patch that accompanies the tablets is a wearable sensor that detects a signal from the IEM sensor after the tablet is ingested and transmits data to a smartphone within 30 minutes to 2 hours of ingestion. If the detection system fails (ie, tablet is not detected after ingestion), do not repeat the dose. Before use, ensure that the patient is capable and willing to use smartphones and apps, that the app is compatible with the patient's specific smartphone, and that the smartphone is paired with the patch prior to use. There are 2 types of patches; refer to corresponding instructions for use within the app. Apply the 1-component patch only when instructed by the app to the left side of the body just above the lower edge of the rib cage. Apply the 2-component patch only when instructed by the app to the left or right side of the body just above the lower edge of the rib cage. Do not place the patch in areas where the skin is scraped, cracked, inflamed, or irritated, or in a location that overlaps the area of the most recently removed patch. Instruct patients to keep the patch on when showering, swimming, or exercising. The patch should be changed weekly or sooner as needed. The app will prompt patient to change the patch and will direct patient to apply and remove the patch correctly. Patients undergoing an MRI need to remove their patch and replace with a new one as soon as possible. If there is skin irritation, instruct patients to remove the patch. Refer to the information provided in the product packaging and electronic instructions for use with the Mycite app.</p></div>
<div class="block sts drugH1Div" id="F136797"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Monthly injection, powder (extended release; Abilify Maintena):</p>
<p style="text-indent:-2em;margin-left:4em;">Prefilled syringe: Store below 30°C (86°F). Do not freeze. Protect from light and store in original package.</p>
<p style="text-indent:-2em;margin-left:4em;">Vial for reconstitution: Store unused vials at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). If the suspension is not administered immediately after reconstitution, store at room temperature in the vial (do not store in a syringe).</p>
<p style="text-indent:-2em;margin-left:2em;">Every-2-months injection, prefilled syringe (extended release; Abilify Asimtufii): Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution and tablets: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Use oral solution within 6 months after opening. Do not store in conditions where tablets are exposed to humid conditions.</p>
<p style="text-indent:-2em;margin-left:2em;">Mycite Patch: Store at 5°C to 27°C (41°F to 81°F); 15% to 93% relative humidity.</p></div>
<div class="block meg drugH1Div" id="F7874282"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Abilify: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F021436s044s045%2C021713s035s036%2C021729s027s028%2C021866s029s030lbl.pdf%23page%3D77&amp;token=3G7XlZnNbBPN%2BfXhgM2ioc0Xx9l0qjjI64DSaWQ7xhdBGId4QZmzWRzRcGK1j73mMuaIlYv%2BfOsbFP9l9sbZBAvj7B3elxU2P1LZWJKW9RD4IIBq%2Bu7%2BTGWAtx0QUNkuKNdttvBa35jhNgyzg6laTSbOKofcg7T1LruKPldkE%2BU%3D&amp;TOPIC_ID=13180" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021436s044s045,021713s035s036,021729s027s028,021866s029s030lbl.pdf#page=77</a></p>
<p style="text-indent:-2em;margin-left:4em;">Abilify Maintena: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F202971s013lbl.pdf%23page%3D52&amp;token=wRZ5Yz88Z7%2FoL2u%2BqGK5HqRHbW8298EnkNyXUfu1KegppBbQq3ggoTyOI4v4FBAlUi3Ui8BE%2BjK6NsbTdvIZcLA0tcdh3qfkq2VsjRSdUhuI8gnLwdqoWB0U6f0Hb2Js&amp;TOPIC_ID=13180" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202971s013lbl.pdf#page=52</a></p>
<p style="text-indent:-2em;margin-left:4em;">Abilify MyCite: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F021436s048lbl.pdf%23page%3D47&amp;token=VOtt8MakdyRvlot79KVZva2WSTzYvIv6G2HI0kEClTZAmdSMssumQqWLy78IYO3zMrA7oe2IbOeqixqaMd07eb%2BadmkukuUGlXl8Rg6KovTdSiJnOR%2B9fblP1ZmcX3sX&amp;TOPIC_ID=13180" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021436s048lbl.pdf#page=47</a></p></div>
<div class="block usep drugH1Div" id="F53565514"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Acute and maintenance treatment of schizophrenia (FDA approved in ages ≥13 years and adults); acute treatment of bipolar I disorder (with acute mania or with mixed features) (FDA approved in ages ≥10 years and adults); adjunctive therapy (to lithium or valproate) for acute treatment of bipolar disorder (with acute mania or with mixed features) (FDA approved in ages ≥10 years and adults); treatment of irritability associated with autistic disorder (FDA approved in ages 6 to 17 years); treatment of Tourette disorder (FDA approved in ages 6 to 18 years); adjunctive treatment (to antidepressants) of major depressive disorder (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Injection:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Acute treatment of agitation associated with schizophrenia or bipolar disorder (manic or mixed) (Abilify: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Treatment of schizophrenia (Abilify Maintena, Abilify Asimtufii: FDA approved in adults); maintenance monotherapy treatment of bipolar disorder (Abilify Asimtufii: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F136828"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Abilify may be confused with Ambien</p>
<p style="text-indent:-2em;margin-left:4em;">ARIPiprazole may be confused with proton pump inhibitors (dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, RABEprazole)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications, including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy for major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">There are two ER formulations available for IM administration: Aripiprazole <b>monohydrate</b> (Abilify Maintena) and aripiprazole <b>lauroxil</b> (Aristada and Aristada Initio).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F136814"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F136768"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk of neuroleptic malignant syndrome or increased QTc interval may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Armodafinil: May decrease the serum concentration of ARIPiprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of ARIPiprazole. Management: Aripiprazole dose reductions or avoidance are required for indications other than major depressive disorder. Dose adjustments vary based on formulation, initial starting dose, and the additional use of CYP3A4 inhibitors. See interact monograph for details<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of ARIPiprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of ARIPiprazole. Management: For indications other than major depressive disorder: double the oral aripiprazole dose over 1 to 2 weeks and closely monitor. Avoid use of strong CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of ARIPiprazole. Management: Aripiprazole dose reductions are required for indications other than major depressive disorder. Dose reductions vary based on formulation, initial starting dose, CYP2D6 genotype, and use of CYP2D6 inhibitors. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of ARIPiprazole. Trimeprazine may increase the serum concentration of ARIPiprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F136798"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Ingestion of oral formulations with a high-fat meal delays time to peak plasma level. Management: Administer without regard to meals.</p></div>
<div class="block dic drugH1Div" id="F136786"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine.</p></div>
<div class="block rep_considerations drugH1Div" id="F54119856"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">If treatment is needed in a woman planning a pregnancy, use of an agent other than aripiprazole is preferred (Larsen 2015).</p></div>
<div class="block pri drugH1Div" id="F136784"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Aripiprazole crosses the placenta; aripiprazole and dehydro-aripiprazole can be detected in the cord blood at delivery (Nguyen 2011; Watanabe 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (Yonkers 2009). The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited, as such, routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to an agent that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is initiated during pregnancy, use of an agent other than aripiprazole is preferred (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers are encouraged to enroll women exposed to aripiprazole during pregnancy in the National Pregnancy Registry for Atypical Antipsychotics (866-961-2388 or http://www.womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/).</p></div>
<div class="block mopp drugH1Div" id="F53565515"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs; CBC with differential; fasting lipid profile and fasting blood glucose/HbA<sub>1c</sub> (prior to treatment, at 3 months, then annually); weight, growth, BMI, and waist circumference (especially in children), personal/family history of diabetes, blood pressure, mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS). Weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals. Consider titrating to a different antipsychotic agent for a weight gain ≥5% of the initial weight. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased).</p></div>
<div class="block pha drugH1Div" id="F136763"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Aripiprazole is a quinolinone antipsychotic which exhibits high affinity for D<sub>2</sub>, D<sub>3</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>2A</sub> receptors; moderate affinity for D<sub>4</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>7</sub>, alpha<sub>1</sub> adrenergic, and H<sub>1</sub> receptors. It also possesses moderate affinity for the serotonin reuptake transporter; has no affinity for muscarinic (cholinergic) receptors. Aripiprazole functions as a partial agonist at the D<sub>2</sub> and 5-HT<sub>1A</sub> receptors, and as an antagonist at the 5-HT<sub>2A</sub> receptor (de Bartolomeis 2015).</p></div>
<div class="block phk drugH1Div" id="F136780"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>In pediatric patients 10 to 17 years of age, the pharmacokinetic parameters of aripiprazole and dehydro-aripiprazole have been shown to be similar to adult values when adjusted for weight.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Bipolar disorder, acute mania: Initial effects may be observed within days of treatment with continued improvements over 1 to 2 weeks (Goikolea 2013; Tohen 2000; Welten 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Major depressive disorder, unipolar: Initial effects may be observed within 1 week with continued improvements over 6 to 12 weeks (Wen 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">Schizophrenia: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 6 weeks (Agid 2003; Levine 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Extended-release: Slow, prolonged.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 4.9 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ≥99%, primarily to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic dehydrogenation, hydroxylation and N-dealkylation via CYP2D6, CYP3A4 (dehydro-aripiprazole metabolite has affinity for D<sub>2</sub> receptors similar to the parent drug and represents 40% of the parent drug exposure in plasma) (Sheehan 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tablet: 87%; <b>Note: </b>Orally disintegrating tablets are bioequivalent to tablets; oral solution to tablet ratio of geometric mean for peak concentration is 122% and for AUC is 114%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours; IM, monthly injection extended release (terminal): ~30 to 47 days (dose-dependent).</p>
<p style="text-indent:-2em;margin-left:4em;">CYP2D6 poor metabolizers: Aripiprazole: 146 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">IM, extended release:</p>
<p style="text-indent:-2em;margin-left:6em;">Monthly injection (Abilify Maintena): After multiple doses, 4 days with deltoid administration and 5 to 7 days with gluteal administration.</p>
<p style="text-indent:-2em;margin-left:6em;">Every-2-months injection (Abilify Asimtufii): After multiple doses, a flat plasma concentration profile is maintained from days 1 through 49.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: 3 to 5 hours; high-fat meals delay time to peak by 3 hours for aripiprazole and 12 hours for dehydro-aripiprazole.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (55%, ~18% of the total dose as unchanged drug; 37% of the total dose as changed drug); urine (25%, &lt;1% of the total dose as unchanged drug; 25% of the total dose as changed drug) (Sheehan 2010)</p></div>
<div class="block phksp drugH1Div" id="F51220446"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In severe renal impairment (CrCl &lt;30 mL/minute), C<sub>max</sub> increased by 36% (aripiprazole) and 53% (dehydro-aripiprazole), but AUC was 15% lower for aripiprazole and 7% higher for dehydro-aripiprazole.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC increased by 31% in mild hepatic impairment and by 8% in moderate impairment, and decreased by 20% in severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: In patients ≥65 years of age who were administered a single oral dose, clearance was 20% lower than that observed in younger patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: C<sub>max</sub> and AUC are 30% to 40% higher in women than in men.</p>
<p style="text-indent:-2em;margin-left:2em;">CYP 2D6 metabolizers: 60% higher exposure to aripiprazole and active metabolites in poor CYP 2D6 metabolizers compared to extensive metabolizers (Sheehan 2010).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539821"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Apiexel | Calmilifi | Compify | Deripex | Librio | Zolinda</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Arinova | Arisdar | Arixind | Arizic | Groven | Ibaral | Irazem | Lemidal | Siblix</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Arileto | Aripiprazol +pharma | Aripiprazol accord | Aripiprazol easypharm | Aripiprazol g.l | Aripiprazol genericon | Aripiprazol krka | Aripiprazol neuraxpharm | Aripiprazol ratiopharm | Aripiprazol sandoz | Aripiprazol stada | Aripiprazole accord | Lemilvo</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Abyraz | Apo aripiprazole | Aripiprazole an | Aripiprazole gh | Aripiprazole sandoz | Tevaripiprazole</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aripen | Aripra | Ariprazole | Ariprex | Sizopra</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazol focus | Aripiprazole eg | Aripiprazole mylan pharma | Aripiprazole sandoz | Aripiprazole teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Abizol | Aricogan | Aripicon | Aripipa | Aripiprazol accord | Aripiprazole aurobindo | Aripiprazole sandoz | Explemed | Explemed rapid | Lemilvo | Restigulin | Zykalor</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Aipri | Aripiprazol | Aripiprazol novartis | Aripiprazol sandoz | Aristab | Biquiz | Confilify | Harip | Hedd | Kavium | Sensaz | Toarip</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazol mepha | Aripiprazol mepha oro | Aripiprazol mylan | Aripiprazol nobel | Aripiprazol sandoz | Aripiprazol spirig hc | Aripiprazol zentiva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Aripir | Arivitae | Arizol | Azymol | Ilimit | Irazem | Irazem odt | Viza</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An lv fan | Ao pai | Bo si qing | Brisking | Fen le</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Ariprax Alpex | Ariprazol | Aripsi | Arivitae | Azymol | Bisoza | Ilimit | Ipipral | Irazem | Prazentol | Strozoven | Zolapril</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aricogan | Aripiprazol | Aripiprazol +pharma | Aripiprazol apotex | Aripiprazol glenmark | Aripiprazole accord | Aripiprazole sandoz | Aripiprazole teva | Aripiprazole zentiva | Aryzalera | Asduter | Explemed | Explemed rapid | Lazurex | Lemilvo | Restigulin | Zykalor</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Arigen | Aripihexal | Aripipan | Aripiprazol | Aripiprazol 1a pharma | Aripiprazol abz | Aripiprazol al | Aripiprazol amneal | Aripiprazol aurobindo | Aripiprazol Axiromed | Aripiprazol beta | Aripiprazol biomo | Aripiprazol glenmark | Aripiprazol hetero | Aripiprazol heumann | Aripiprazol hexal | Aripiprazol hormosan | Aripiprazol krka | Aripiprazol macleods | Aripiprazol neuraxpharm | Aripiprazol puren | Aripiprazol ratiopharm | Aripiprazol stada | Aripiprazol zentiva | Arpilif | Arpoya</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aritero | Ilimit | Pezil</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Arilex Ft | Arizol | Arpizol | Azymol | Ilimit</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aricogan | Aripiprazole accord | Aripiprazole mylan | Aripiprazole teva | Aripiprazole zentiva | Arisppa | Lemilvo | Paxifor | Zykalor</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Abilia | Abilify | Adwiprazole | Apilipex | Apipe | Arepexane | Aripipracare | Aripiprex | Centalify | Prazolosab | Schizofy | Schizostop</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Abik | Abilify | Abilify maintena | Apaloz | Aripiprazol | Aripiprazol accord | Aripiprazol almus | Aripiprazol alter | Aripiprazol amneal | Aripiprazol apotex | Aripiprazol aurovitas | Aripiprazol bexal | Aripiprazol combix | Aripiprazol focus | Aripiprazol kern pharma | Aripiprazol krka | Aripiprazol mabo | Aripiprazol Mylan Pharma | Aripiprazol mylan pharmaceuticals | Aripiprazol normon | Aripiprazol pensa | Aripiprazol Qualigen | Aripiprazol ratiopharm | Aripiprazol sandoz | Aripiprazol stada | Aripiprazol Tarbis | Aripiprazol tecnigen | Aripiprazol teva | Aripiprazol vir | Aripiprazol zentiva | Arizol | Arizol flas | Atildon flas | Tractiva | Zykalor</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazol krka | Aripiprazol stada | Aripiprazole accord | Aripiprazole orion | Aripiprazole ratiopharm | Lemilvo</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazol almus | Aripiprazole accord | Aripiprazole arrow | Aripiprazole BGR | Aripiprazole biogaran | Aripiprazole eg | Aripiprazole evolugen | Aripiprazole focus | Aripiprazole mylan | Aripiprazole mylan pharma | Aripiprazole sandoz | Aripiprazole teva | Aripiprazole zentiva | Aripiprazole zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazole accord | Aripiprazole Dr. Reddy's | Aripiprazole milpharm | Aripiprazole niche | Aripiprazole Pharmathen | Aripiprazole rivopharm | Aripiprazole sandoz | Aripiprazole zentiva | Arpoya</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Abelfiz | Abilify | Abilify maintena | Anasil | Aripiprazole mylan pharma | Aripiprazole sandoz | Aripiprazole/genepharm | Arpilif | Arpoya | Epimat | Prazarit | Rapiproz | Zykalor</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aryzalera</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazol mylan | Aripiprazol Pliva | Arisppa | Azolar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aricogan | Aripiprazol | Aripiprazol sandoz | Aripiprazol stada | Aripiprazole mylan pharma | Aripiprazole orion | Aripiprazole zentiva | Arisppa | Asduter | Explemed | Lemilvo | Piprason | Restigulin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Arinia | Ariski | Zipren</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazole accord | Aripiprazole clonmel | Aripiprazole focus | Aripiprazole Pinewood | Aripiprazole sandoz | Lemilvo</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">ARIPLY</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Apicord | Apiz | Aprizol | Apz | Arerep | Aria | Ariday | Aridus | Arifine | Ariford md | Arifril | Arilan | Arinex | Arip mt | Aripamat | Aripat md | Ariphrenz | Aripicad | Aripicon | Aripiren | Aripitex | Aripkon | Aripra | Arirazo | Arive | Ariza | Arize | Arpit | Arpizol | Arza | Arzu | Asprito | Bilif | Elrip | Nulet | Pipra a | Real one | Rizotal | Schizopra</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Abilify</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aberipra | Abilify | Abilify maintena | Aripiprazolo accord | Aripiprazolo Aurobindo | Aripiprazolo doc | Aripiprazolo doc generici | Aripiprazolo eg | Aripiprazolo focus | Aripiprazolo macleods | Aripiprazolo mylan generics | Aripiprazolo mylan pharma | Aripiprazolo sandoz | Aripiprazolo sandoz gmbh | Aripiprazolo teva | Aripiprazolo teva italia | Aripiprazolo zentiva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Arina | Arpenia | Zorta</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify asimtufii | Aripiprazole amel | Aripiprazole kyorin | Aripiprazole meiji | Aripiprazole od | Aripiprazole ohara | Aripiprazole sawai | Aripiprazole towa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Arip 15 | Aripitas</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Abilapin | Abilify | Abilify maintena | Apizol | Arabil | Arazol | Arify | Aripico | Aripione | Aripizin | Aripizol | Aripra | Arizole | Bearbilly | Boryung aripiprazole | Cypi | Hanlim aripiprazole | Repizole | Samsung aripiprazole | Sandoz aripiprazole</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Zolinda</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Abilify maintena | Aripal | Atypral | Xalipro</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aricogan | Aripiprazole accord | Aripiprazole mylan | Aripiprazole pmcs | Arisppa | Lemilvo | Paxifor | Zykalor</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazol ratiopharm | Aripiprazol sandoz | Aripiprazole eg | Aripiprazole mylan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aricogan | Aripiprazole accord | Aripiprazole mylan | Aripiprazole teva | Aripiprazole zentiva | Arisppa | Lemilvo | Paxifor | Zykalor</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Aripiphi | Fadof</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Antredamin | Aripiprazol | Atfren | Hetezon | Laprinz | Motruxia | Ripizolnev</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Apalife | Arian | Arian 15 | Arilift | Arip mt | Ariptor</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Aqeud</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazol | Aripiprazol aurobindo | Aripiprazol cf | Aripiprazol medcor | Aripiprazol mylan | Aripiprazol sandoz | Aripiprazol xiromed | Aripiprazole accord</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazole accord | Aripiprazole medical valley | Aripiprazole mylan | Aripiprazole sandoz | Lemilvo</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazole sandoz</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Aripral | Arpizol | Azymol | Gemplex | Irazem | Irix | Lepiren</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Abdin | Abilify | Arizopress | Bisoza</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adablizer | Alcartis | Apify | Aplefi | Arify | Arigit | Aripex | Aripip | Arizole | Karipel | Liprazole | Mactril | Pipzol | Profy | Zorip</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Apiprax | Apra | Apra swift | Aribit | Aribit odt | Aricogan | Aripilek | Aripiprazole +pharma | Aripiprazole accord | Aripiprazole apotex | Aripiprazole mylan | Aripiprazole NeuroPharma | Aripiprazole sandoz | Aripiprazole stada | Aripiprazole Symphar | Aripiprazole zentiva | Aripsan | Arpixor | Arypiprazol glenmark | Aryzalera | Asduter | Explemed | Explemed rapid | Lemilvo | Preheftari</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Abilify Maintena kit | Abilify mycite</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Altedron | Aripipr mg zidrium | Aripiprazol alter | Aripiprazol aurobindo | Aripiprazol aurovitas | Aripiprazol baldacci | Aripiprazol Ciclum | Aripiprazol cinfa | Aripiprazol farmoz | Aripiprazol Generis | Aripiprazol jaba | Aripiprazol kipa | Aripiprazol krka | Aripiprazol Mylan Pharma | Aripiprazol pentafarma | Aripiprazol pharmakern | Aripiprazol ratiopharm | Aripiprazol tetrafarma | Aripiprazol teva | Aripiprazol tolife | Aripiprazol zentiva | Arpixor</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Azymol | Ilimit | Sicopax</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify Maintena | Zinole</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aricogan | Aripiprazol aurobindo | Aripiprazol glenmark | Aripiprazol sandoz | Aripiprazol stada | Aripiprazol teva | Aripiprazole accord | Aripiprazole zentiva | Aryzalera | Astoret | Explemed | Lemilvo | Restigulin | Zykalor</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Alembik pipzol | Amdoal | Aripiprazole od teva | Aripiprazole teva | Ariprisol | Ariprizol | Mirium | Zylaksera | Zylaxera</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Abilirazole | Apiexel | Aripal | Aripex | Arpenia | Zolinda | Zorta</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazol amneal | Aripiprazol ebb | Aripiprazol krka | Aripiprazol sandoz | Aripiprazol stada | Aripiprazole accord | Aripiprazole medical valley | Aripiprazole sandoz | Aripiprazole teva | Aripiprazole zentiva | Lemilvo</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aripiprazol accord | Aripiprazol mylan | Aripiprazol sandoz | Aripiprazol stada | Aripiprazol teva | Aryzalera | Lemilvo | Zykalor</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Aricogan | Arimed | Aripiprazol glenmark | Aripiprazol mylan | Aripiprazol sandoz | Aripiprazol stada | Aripiprazol teva | Aripiprazole accord | Aripiprazole neuraxpharm | Aripiprazole sandoz | Aripiprazole zentiva | Arisppa | Asduter | Explemed rapid | Lemilvo | Restigulin | Zykalor</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Apalife</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Abilicare | Abilify</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Abizol | Arifay | Aripa | Curexol | Egisazol | Ignis | Madepzol | Oryva | Ripazol | Sayfren | Zolerip</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Abimay | Albifine | Apa bily | Apraz | Arify | Arika | Aripizole | Ariple | Aritero | Arizole | Ezole | Otsuka abilify | Ripra | Zydus Aripiprazole</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abizol | Abizol easytab | Arilental | Arip mt | Ariprazol | Freym | Mintegra | Mirium | Zykalor | Zylaxera</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Arip 15 | Ilimit | Ilipra</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Ariprin | Irmil</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Ariazol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Abilify | Abilify maintena | Abipip | Alebon | Apripent | Aprizon | Aripiprazole cipla | Aripiprazole mylan | Arizofy | Priptrin | Prizal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Abilify (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; June 2020</div>
</li>
<li>
<div class="reference">
                  Abilify (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; November 2022.</div>
</li>
<li>
<div class="reference">
                  Abilify Asimtufii (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; April 2023.</div>
</li>
<li>
<div class="reference">
                  Abilify Asimtufii (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; August 2023.</div>
</li>
<li>
<div class="reference">
                  Abilify Maintena (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; June 2020.</div>
</li>
<li>
<div class="reference">
                  Abilify Maintena (aripiprazole) [product monograph]. Saint-Laurent, Quebec, Canada: Otsuka Canada Pharmaceutical Inc; March 2021.</div>
</li>
<li>
<div class="reference">
                  Abilify Maintena (aripiprazole) [product monograph]. Saint-Laurent, Quebec, Canada: Otsuka Canada Pharmaceutical Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AbilifyMycite.1">
<a name="AbilifyMycite.1"></a>Abilify Mycite (aripiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation. <i>Obstet Gynecol.</i> 2008;111(4):1001-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14662555">
<a name="14662555"></a>Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. <i>Arch Gen Psychiatry</i>. 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/14662555/pubmed" id="14662555" target="_blank">14662555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30730330">
<a name="30730330"></a>Agrawal A, Bajaj D, Bajaj S, Mattana J. Aripiprazole induced late neuroleptic malignant syndrome. <i>Am J Ther</i>. 2019;26(6):e772-e773. doi:10.1097/MJT.0000000000000944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30730330/pubmed" id="30730330" target="_blank">30730330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30949057">
<a name="30949057"></a>Aguilar L, Lorenzo C, Fernández-Ovejero R, Roncero C, Montejo AL. Tardive dyskinesia after aripiprazole treatment that improved with tetrabenazine, clozapine, and botulinum toxin. <i>Front Pharmacol</i>. 2019;10:281. doi:10.3389/fphar.2019.00281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30949057/pubmed" id="30949057" target="_blank">30949057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35582951">
<a name="35582951"></a>Ahmed A, Affleck AG, Angus J, et al; British Association of Dermatologists' Clinical Standards Unit. British Association of Dermatologists guidelines for the management of adults with delusional infestation 2022. <i>Br J Dermatol.</i> 2022;187(4):472-480. doi:10.1111/bjd.21668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/35582951/pubmed" id="35582951" target="_blank">35582951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21437763">
<a name="21437763"></a>Ak M, Bulut SD, Bozkurt A, Ozsahin A. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. <i>Adv Ther</i>. 2011;28(4):341-348. doi:10.1007/s12325-011-0011-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21437763/pubmed" id="21437763" target="_blank">21437763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27093218">
<a name="27093218"></a>Al-Dhaher Z, Kapoor S, Saito E, et al. Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in youth. <i>J Child Adolesc Psychopharmacol</i>. 2016;26(5):458-470. doi:10.1089/cap.2015.0141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/27093218/pubmed" id="27093218" target="_blank">27093218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31524318">
<a name="31524318"></a>Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: A systematic review. <i>Obes Rev</i>. 2019;20(12):1680-1690. doi:10.1111/obr.12934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/31524318/pubmed" id="31524318" target="_blank">31524318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747245">
<a name="14747245"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>Diabetes Care</i>. 2004;27(2):596-601. doi:10.2337/diacare.27.2.596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/14747245/pubmed" id="14747245" target="_blank">14747245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association, 2007. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/ocd.pdf. Published July 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28861176">
<a name="28861176"></a>Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. <i>World J Diabetes</i>. 2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28861176/pubmed" id="28861176" target="_blank">28861176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30375086">
<a name="30375086"></a>Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. <i>Psychiatry Clin Neurosci</i>. 2019;73(1):27-33. doi:10.1111/pcn.12793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30375086/pubmed" id="30375086" target="_blank">30375086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aripiprazole.2">
<a name="Aripiprazole.2"></a>Aripiprazole orally disintegrating tablets [prescribing information]. Cranford, NJ: Viona Pharmaceuticals; July 2022.</div>
</li>
<li>
<div class="reference">
                  Aripiprazole solution [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA, Inc; April 2023.</div>
</li>
<li>
<div class="reference">
                  Aripiprazole solution [prescribing information]. Weston, FL: Apotex; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900217">
<a name="35900217"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part II: OCD and PTSD. <i>World J Biol Psychiatry.</i> 2023;24(2):118-134. doi:10.1080/15622975.2022.2086296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/35900217/pubmed" id="35900217" target="_blank">35900217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9712220">
<a name="9712220"></a>Bark N. Deaths of psychiatric patients during heat waves. <i>Psychiatr Serv</i>. 1998;49(8):1088-1090. doi:10.1176/ps.49.8.1088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/9712220/pubmed" id="9712220" target="_blank">9712220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25578944">
<a name="25578944"></a>Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. <i>Drugs R D</i>. 2015;15(1):45-62. doi:10.1007/s40268-014-0078-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/25578944/pubmed" id="25578944" target="_blank">25578944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19407731">
<a name="19407731"></a>Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. <i>CNS Spectr</i>. 2009;14(4):197-206. doi:10.1017/s1092852900020216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19407731/pubmed" id="19407731" target="_blank">19407731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21655344">
<a name="21655344"></a>Berman RM, Thase ME, Trivedi MH, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. <i>Neuropsychiatr Dis Treat</i>. 2011;7:303-312. doi:10.2147/NDT.S18333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21655344/pubmed" id="21655344" target="_blank">21655344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27395403">
<a name="27395403"></a>Bernagie C, Danckaerts M, Wampers M, De Hert M. Aripiprazole and acute extrapyramidal symptoms in children and adolescents: A meta-analysis. <i>CNS Drugs</i>. 2016;30(9):807-818. doi:10.1007/s40263-016-0367-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/27395403/pubmed" id="27395403" target="_blank">27395403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17698676">
<a name="17698676"></a>Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. <i>Arch Intern Med</i>. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17698676/pubmed" id="17698676" target="_blank">17698676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19170197">
<a name="19170197"></a>Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. <i>Mov Disord</i>. 2009;24(1):126-129. doi:10.1002/mds.22376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19170197/pubmed" id="19170197" target="_blank">19170197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28033456">
<a name="28033456"></a>Bulbena-Cabré A, Bulbena A. Aripiprazole-induced hypersexuality. <i>Prim Care Companion CNS Disord</i>. 2016;18(6):10.4088/PCC.16l01983. doi:10.4088/PCC.16l01983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28033456/pubmed" id="28033456" target="_blank">28033456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18468728">
<a name="18468728"></a>Campanella LM, Lartey R, Shih R. Severe hyperglycemic hyperosmolar nonketotic coma in a nondiabetic patient receiving aripiprazole. <i>Ann Emerg Med</i>. 2009;53(2):264-266. doi:10.1016/j.annemergmed.2008.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18468728/pubmed" id="18468728" target="_blank">18468728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30543832">
<a name="30543832"></a>Campbell EH, Elston DM, Hawthorne JD, Beckert DR. Diagnosis and management of delusional parasitosis.<i> J Am Acad Dermatol</i>. 2019;80(5):1428-1434. doi:10.1016/j.jaad.2018.12.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30543832/pubmed" id="30543832" target="_blank">30543832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16529334">
<a name="16529334"></a>Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/16529334/pubmed" id="16529334" target="_blank">16529334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28146614">
<a name="28146614"></a>Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. <i>J Clin Psychiatry</i>. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28146614/pubmed" id="28146614" target="_blank">28146614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33976948">
<a name="33976948"></a>Carbone MG, Tagliarini C, Della Rocca F, et al. Protracted hiccups induced by aripiprazole and regressed after administration of gabapentin. <i>Case Rep Psychiatry</i>. 2021;2021:5567152. doi:10.1155/2021/5567152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/33976948/pubmed" id="33976948" target="_blank">33976948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30888439">
<a name="30888439"></a>Cardinale M, Cungi PJ, Meaudre E. Green plasma and a blocked CRRT circuit due to drug-induced hyperlipidemia. <i>Intensive Care Med</i>. 2019;45(9):1305-1306. doi:10.1007/s00134-019-05592-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30888439/pubmed" id="30888439" target="_blank">30888439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172575">
<a name="21172575"></a>Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. <i>Neurol Clin</i>. 2011;29(1):127-viii. doi:10.1016/j.ncl.2010.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21172575/pubmed" id="21172575" target="_blank">21172575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151456">
<a name="15151456"></a>Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. <i>J Clin Psychiatry</i>. 2004;65(suppl 7):4-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/15151456/pubmed" id="15151456" target="_blank">15151456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23821039">
<a name="23821039"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi:10.1007/s40263-013-0079-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23821039/pubmed" id="23821039" target="_blank">23821039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22234928">
<a name="22234928"></a>Chen Y, Bobo WV, Watts K, Jayathilake K, Tang T, Meltzer HY. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. <i>J Psychopharmacol</i>. 2012;26(9):1201-1210. doi:10.1177/0269881111430748<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/22234928/pubmed" id="22234928" target="_blank">22234928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16176209">
<a name="16176209"></a>Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. <i>Diabet Med</i>. 2005;22(10):1440-1443. doi:10.1111/j.1464-5491.2005.01628.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/16176209/pubmed" id="16176209" target="_blank">16176209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19557093">
<a name="19557093"></a>Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington's disease: a case series. <i>Neuropsychiatr Dis Treat</i>. 2009;5:1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19557093/pubmed" id="19557093" target="_blank">19557093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24666104">
<a name="24666104"></a>Citrome L, Kalsekar I, Baker RA, Hebden T. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. <i>Curr Med Res Opin</i>. 2014;30(8):1629-1641. doi:10.1185/03007995.2014.908280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24666104/pubmed" id="24666104" target="_blank">24666104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26963842">
<a name="26963842"></a>Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. <i>Int Clin Psychopharmacol</i>. 2016;31(4):192-201. doi:10.1097/YIC.0000000000000123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/26963842/pubmed" id="26963842" target="_blank">26963842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28141623">
<a name="28141623"></a>Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. <i>J Clin Psychopharmacol</i>. 2017;37(2):138-147. doi:10.1097/JCP.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28141623/pubmed" id="28141623" target="_blank">28141623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18533766">
<a name="18533766"></a>Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. <i>J Clin Psychiatry</i>. 2008;69 Suppl 4:26-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18533766/pubmed" id="18533766" target="_blank">18533766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19861668">
<a name="19861668"></a>Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents [published correction appears in JAMA. 2009 Dec 2;302(21):2322]. <i>JAMA</i>. 2009;302(16):1765-1773. doi:10.1001/jama.2009.1549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19861668/pubmed" id="19861668" target="_blank">19861668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33612035">
<a name="33612035"></a>Cox JH, Cavanna AE. Aripiprazole for the treatment of Tourette syndrome. <i>Expert Rev Neurother</i>. 2021;21(4):381-391. doi:10.1080/14737175.2021.1893693<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/33612035/pubmed" id="33612035" target="_blank">33612035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26237252">
<a name="26237252"></a>Cox JH, Seri S, Cavanna AE. Clinical guidelines on long-term pharmacotherapy for bipolar disorder in children and adolescents. <i>J Clin Med</i>. 2014;3(1):135-143. doi:10.3390/jcm3010135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/26237252/pubmed" id="26237252" target="_blank">26237252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955499">
<a name="29955499"></a>Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: A case report and review of the literature. <i>Ment Health Clin</i>. 2018;7(2):56-64. doi:10.9740/mhc.2017.03.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/29955499/pubmed" id="29955499" target="_blank">29955499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28883731">
<a name="28883731"></a>Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. <i>Neuropsychiatr Dis Treat</i>. 2017;13:2231-2241. doi:10.2147/NDT.S113099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28883731/pubmed" id="28883731" target="_blank">28883731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26346901">
<a name="26346901"></a>de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. <i>CNS Drugs. </i> 2015;29(9):773-799.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/26346901/pubmed" id="26346901" target="_blank">26346901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16160622">
<a name="16160622"></a>De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. <i>J Clin Psychopharmacol</i>. 2005;25(5):463-467.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/16160622/pubmed" id="16160622" target="_blank">16160622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22009159">
<a name="22009159"></a>De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nat Rev Endocrinol</i>. 2011;8(2):114-126. doi:10.1038/nrendo.2011.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/22009159/pubmed" id="22009159" target="_blank">22009159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28102975">
<a name="28102975"></a>Dhillon R, Bastiampillai T, Cao CZ, Eckert TG, Tibrewal P. Aripiprazole and impulse-control disorders: a recent FDA warning and a case report. <i>Prim Care Companion CNS Disord</i>. 2017;19(1):10.4088/PCC.16l02003. doi:10.4088/PCC.16l02003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28102975/pubmed" id="28102975" target="_blank">28102975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26508859">
<a name="26508859"></a>Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. <i>Neuropsychiatr Dis Treat</i>. 2015;11:2635-2647. doi:10.2147/NDT.S88117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/26508859/pubmed" id="26508859" target="_blank">26508859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21993869">
<a name="21993869"></a>Ercan ES, Uysal T, Ercan E, Akyol Ardic U. Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study. <i>Pharmacopsychiatry</i>. 2012;45(1):13-19. doi:10.1055/s-0031-1286348<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21993869/pubmed" id="21993869" target="_blank">21993869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27580493">
<a name="27580493"></a>Etminan M, Procyshyn RM, Samii A, Carleton BC. Risk of extrapyramidal adverse events with aripiprazole. <i>J Clin Psychopharmacol</i>. 2016;36(5):472-474. doi:10.1097/JCP.0000000000000543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/27580493/pubmed" id="27580493" target="_blank">27580493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17414689">
<a name="17414689"></a>Evcimen H, Alici-Evcimen Y, Basil B, Mania I, Mathews M, Gorman JM. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis. <i>J Psychiatr Pract</i>. 2007;13(2):117-119. doi:10.1097/01.pra.0000265770.17871.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17414689/pubmed" id="17414689" target="_blank">17414689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29715374">
<a name="29715374"></a>Felin T, Naveed S, Chaudhary AM. Aripiprazole-induced neutropenia: case report and literature review. <i>J Psychosoc Nurs Ment Health Serv</i>. 2018;56(5):21-24. doi:10.3928/02793695-20180419-02<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/29715374/pubmed" id="29715374" target="_blank">29715374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19702495">
<a name="19702495"></a>Findling RL, Kauffman R, Sallee FR, et al. An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents With Conduct Disorder. <i>J Child Adolesc Psychopharmacol.</i> 2009;19(4):431-439.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19702495/pubmed" id="19702495" target="_blank">19702495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18098216">
<a name="18098216"></a>Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. <i>Hum Psychopharmacol</i>. 2008;23(suppl 1):27-41. doi:10.1002/hup.917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18098216/pubmed" id="18098216" target="_blank">18098216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24315783">
<a name="24315783"></a>Gaboriau L, Victorri-Vigneau C, Gérardin M, Allain-Veyrac G, Jolliet-Evin P, Grall-Bronnec M. Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. <i>Addict Behav</i>. 2014;39(3):562-565. doi:10.1016/j.addbeh.2013.11.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24315783/pubmed" id="24315783" target="_blank">24315783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21693430">
<a name="21693430"></a>Ganguli R, Brar JS, Garbut R, Chang CC, Basu R. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. <i>Clin Schizophr Relat Psychoses</i>. 2011;5(2):75-79. doi:10.3371/CSRP.5.2.3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21693430/pubmed" id="21693430" target="_blank">21693430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24779650">
<a name="24779650"></a>Garg A, Sinha P, Jyrwa S. Aripiprazole in difficult-to-treat delusional disorder with co-morbid epilepsy. <i>Psychiatry Clin Neurosci</i>. 2014;68(9):721-722. doi:10.1111/pcn.12200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24779650/pubmed" id="24779650" target="_blank">24779650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26912127">
<a name="26912127"></a>Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. <i>World J Biol Psychiatry</i>. 2016;17(2):86-128. doi:10.3109/15622975.2015.1132007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/26912127/pubmed" id="26912127" target="_blank">26912127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27672358">
<a name="27672358"></a>Gerasch S, Kanaan AS, Jakubovski E, Müller-Vahl KR. Aripiprazole improves associated comorbid conditions in addition to tics in adult patients with gilles de la Tourette syndrome. <i>Front Neurosci.</i> 2016;10:416. doi:10.3389/fnins.2016.00416<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/27672358/pubmed" id="27672358" target="_blank">27672358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17548409">
<a name="17548409"></a>Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. <i>Ann Intern Med</i>. 2007;146(11):775-786. doi:10.7326/0003-4819-146-11-200706050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17548409/pubmed" id="17548409" target="_blank">17548409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30849063">
<a name="30849063"></a>Giri YR, Peteru SR. Escalation of gambling associated with aripiprazole: a case report and literature review. <i>J Psychiatr Pract</i>. 2019;25(2):139-145. doi:10.1097/PRA.0000000000000367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30849063/pubmed" id="30849063" target="_blank">30849063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22841129">
<a name="22841129"></a>Goikolea JM, Colom F, Capapey J, et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. <i>Eur Neuropsychopharmacol</i>. 2013;23(4):305-316. doi:10.1016/j.euroneuro.2012.05.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/22841129/pubmed" id="22841129" target="_blank">22841129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21790209">
<a name="21790209"></a>Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. <i>CNS Drugs</i>. 2011;25(8):659-671. doi:10.2165/11591710-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21790209/pubmed" id="21790209" target="_blank">21790209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28487307">
<a name="28487307"></a>Gunasekaran K, Murthi S, Jennings J, Lone N. Aripiprazole-induced hypersensitivity pneumonitis. <i>BMJ Case Rep</i>. 2017;2017:bcr2017219929. doi:10.1136/bcr-2017-219929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28487307/pubmed" id="28487307" target="_blank">28487307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18941580">
<a name="18941580"></a>Hansen A, Bi P, Nitschke M, Ryan P, Pisaniello D, Tucker G. The effect of heat waves on mental health in a temperate Australian city. <i>Environ Health Perspect</i>. 2008;116(10):1369-1375. doi:10.1289/ehp.11339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18941580/pubmed" id="18941580" target="_blank">18941580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834451">
<a name="22834451"></a>Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi:10.3109/15622975.2012.696143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/22834451/pubmed" id="22834451" target="_blank">22834451</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Healthy Canadians Recalls &amp; Alerts. Safety information for antipsychotic drug Abilify and risk of certain impulse-control behaviours. Health Canada website. <a href="http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/55668a-eng.php" target="_blank">http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/55668a-eng.php</a>. Published November 2, 2015. Accessed November 2, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-health.canada.2016">
<a name="health.canada.2016"></a>Healthy Canadians Recalls &amp; Alerts. Summary safety review – atypical antipsychotics – assessing the potential risk of sleep apnoea. Health Canada website. <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-atypical-antipsychotics-assessing-potential-risk-sleep-apnoea.html" target="_blank">https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-atypical-antipsychotics-assessing-potential-risk-sleep-apnoea.html</a>. Published August 16, 2016. Accessed August 23, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23789596">
<a name="23789596"></a>Heller MM, Wong JW, Lee ES, et al. Delusional infestations: clinical presentation, diagnosis and treatment. <i>Int J Dermatol</i>. 2013;52(7):775-783. doi:10.1111/ijd.12067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23789596/pubmed" id="23789596" target="_blank">23789596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW,et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10671383">
<a name="10671383"></a>Howard R, Rabins PV, Seeman MV, Jeste DV; International Late-Onset Schizophrenia Group. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. <i>Am J Psychiatry</i>. 2000;157(2):172-178. doi:10.1176/appi.ajp.157.2.172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/10671383/pubmed" id="10671383" target="_blank">10671383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29924506">
<a name="29924506"></a>Hsu JH, Mulsant BH, Lenze EJ, et al. Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. <i>J Clin Psychiatry</i>. 2018;79(4):17m11764. doi:10.4088/JCP.17m11764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/29924506/pubmed" id="29924506" target="_blank">29924506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30849061">
<a name="30849061"></a>Iannuzzi GL, Patel AA, Stewart JT. Aripiprazole and delusional disorder. <i>J Psychiatr Pract</i>. 2019;25(2):132-134. doi:10.1097/PRA.0000000000000368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30849061/pubmed" id="30849061" target="_blank">30849061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20053539">
<a name="20053539"></a>Isaac M, Koch A. The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia. <i>Eur Neuropsychopharmacol</i>. 2010;20(3):139-145. doi:10.1016/j.euroneuro.2009.12.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/20053539/pubmed" id="20053539" target="_blank">20053539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25140533">
<a name="25140533"></a>Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. <i>PLoS One</i>. 2014;9(8):e105376. doi:10.1371/journal.pone.0105376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/25140533/pubmed" id="25140533" target="_blank">25140533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3819263">
<a name="3819263"></a>Jurivich DA, Hanlon J, Andolsek K. Neuroleptic-induced neutropenia in the elderly. <i>J Am Geriatr Soc</i>. 1987;35(3):248-250. doi:10.1111/j.1532-5415.1987.tb02317.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/3819263/pubmed" id="3819263" target="_blank">3819263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193526">
<a name="22193526"></a>Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. <i>Am J Psychiatry</i>. 2012;169(1):71-79. doi:10.1176/appi.ajp.2011.11030347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/22193526/pubmed" id="22193526" target="_blank">22193526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10686232">
<a name="10686232"></a>Kamin J, Manwani S, Hughes D. Emergency psychiatry: extrapyramidal side effects in the psychiatric emergency service. <i>Psychiatr Serv</i>. 2000;51(3):287-289. doi:10.1176/appi.ps.51.3.287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/10686232/pubmed" id="10686232" target="_blank">10686232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20008446">
<a name="20008446"></a>Kane JM, Barnes TR, Correll CU, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. <i>J Psychopharmacol</i>. 2010;24(7):1019-1029. doi:10.1177/0269881109348157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/20008446/pubmed" id="20008446" target="_blank">20008446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19323965">
<a name="19323965"></a>Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.<i> J Clin Psychiatry</i>. 2009;70(4):572-581. doi:10.4088/jcp.08m04421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19323965/pubmed" id="19323965" target="_blank">19323965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32246399">
<a name="32246399"></a>Keks N, Hope J, Schwartz D, McLennan H, Copolov D, Meadows G. Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. <i>CNS Drugs</i>. 2020;34(5):473-507. doi:10.1007/s40263-020-00718-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/32246399/pubmed" id="32246399" target="_blank">32246399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24385408">
<a name="24385408"></a>Khanna P, Suo T, Komossa K, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. <i>Cochrane Database Syst Rev</i>. 2014;(1):CD006569. doi:10.1002/14651858.CD006569.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24385408/pubmed" id="24385408" target="_blank">24385408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19011427">
<a name="19011427"></a>Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.<i> J Clin Psychopharmacol</i>. 2008;28(6):601-607. doi:10.1097/JCP.0b013e31818aaf6c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19011427/pubmed" id="19011427" target="_blank">19011427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766935">
<a name="12766935"></a>Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. <i>Hum Psychopharmacol</i>. 2003;18(4):301-309. doi:10.1002/hup.483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/12766935/pubmed" id="12766935" target="_blank">12766935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19300045">
<a name="19300045"></a>Kohen I, Sarcevic A. Central sleep apnea in a geriatric patient treated with aripiprazole. <i>Am J Ther</i>. 2009;16(2):197-198. doi:10.1097/MJT.0b013e318186380b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19300045/pubmed" id="19300045" target="_blank">19300045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Koran.2013">
<a name="Koran.2013"></a>Koran LM, Simpson HB. Guideline watch (March 2013): Practice guideline for the treatment of patients with obsessive-compulsive disorder. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/ocd-watch.pdf. Published March 2013. Accessed October 23, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174785">
<a name="16174785"></a>Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. <i>Ann Pharmacother</i>. 2005;39(11):1940-1942. doi:10.1345/aph.1G130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/16174785/pubmed" id="16174785" target="_blank">16174785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23737244">
<a name="23737244"></a>La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. <i>Pharmacopsychiatry</i>. 2013;46(6):201-208. doi:10.1055/s-0033-1347177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23737244/pubmed" id="23737244" target="_blank">23737244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21120263">
<a name="21120263"></a>Ladizinski B, Busse KL, Bhutani T, Koo JY. Aripiprazole as a viable alternative for treating delusions of parasitosis. <i>J Drugs Dermatol</i>. 2010;9(12):1531-1532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21120263/pubmed" id="21120263" target="_blank">21120263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17650054">
<a name="17650054"></a>Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17650054/pubmed" id="17650054" target="_blank">17650054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21058927">
<a name="21058927"></a>Lander M, Bastiampillai T. Neutropenia associated with quetiapine, olanzapine, and aripiprazole. <i>Aust N Z J Psychiatry</i>. 2011;45(1):89. doi:10.3109/00048674.2010.524624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21058927/pubmed" id="21058927" target="_blank">21058927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24016844">
<a name="24016844"></a>Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>Am J Geriatr Psychiatry</i>. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24016844/pubmed" id="24016844" target="_blank">24016844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15000267">
<a name="15000267"></a>Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2)(suppl):1-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/15000267/pubmed" id="15000267" target="_blank">15000267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15845964">
<a name="15845964"></a>Lenzer J. FDA warns about using antipsychotic drugs for dementia. <i>BMJ</i>. 2005;330(7497):922. doi:10.1136/bmj.330.7497.922-c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/15845964/pubmed" id="15845964" target="_blank">15845964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28777129">
<a name="28777129"></a>Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, Garcia M, Aguirre C. Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?. <i>Int Clin Psychopharmacol</i>. 2018;33(1):56-58. doi:10.1097/YIC.0000000000000194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28777129/pubmed" id="28777129" target="_blank">28777129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23810019">
<a name="23810019"></a>Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. <i>Lancet</i>. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23810019/pubmed" id="23810019" target="_blank">23810019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18849294">
<a name="18849294"></a>Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. <i>Schizophr Bull</i>. 2010;36(3):624-632. doi:10.1093/schbul/sbn120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18849294/pubmed" id="18849294" target="_blank">18849294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21541978">
<a name="21541978"></a>Lin TW, Lee BS, Liao YC, Chiu NY, Hsu WY. High dosage of aripiprazole-induced dysphagia. <i>Int J Eat Disord</i>. 2012;45(2):305-306. doi:10.1002/eat.20934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21541978/pubmed" id="21541978" target="_blank">21541978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18765501">
<a name="18765501"></a>Lin WC, Chou YH. Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease. <i>Am J Psychiatry</i>. 2008;165(9):1207-1208. doi:10.1176/appi.ajp.2008.08040503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18765501/pubmed" id="18765501" target="_blank">18765501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20520299">
<a name="20520299"></a>Lutz UC, Hiemke C, Wiatr G, et al. Aripiprazole in pregnancy and lactation: a case report. <i>J Clin Psychopharmacol. </i>2010;30(2):204-205. doi:10.1097/JCP.0b013e3181d27c7d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/20520299/pubmed" id="20520299" target="_blank">20520299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29034139">
<a name="29034139"></a>Majeed MH, Ali AA. Aripiprazole-induced neutropenia in a seven year-old male: a case report. <i>Cureus</i>. 2017;9(8):e1561. doi:10.7759/cureus.1561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/29034139/pubmed" id="29034139" target="_blank">29034139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18752391">
<a name="18752391"></a>Makhzoumi ZH, McLean LP, Lee JH, Ibe AI. Diabetic ketoacidosis associated with aripiprazole. <i>Pharmacotherapy</i>. 2008;28(9):1198-1202. doi:10.1592/phco.28.9.1198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18752391/pubmed" id="18752391" target="_blank">18752391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18611062">
<a name="18611062"></a>Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. <i>Clin Pharmacokinet</i>. 2008;47(8):533-542. doi:10.2165/00003088-200847080-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18611062/pubmed" id="18611062" target="_blank">18611062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manschreck.2019">
<a name="Manschreck.2019"></a>Manschreck T. Delusional disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17503974">
<a name="17503974"></a>Marder SR, West B, Lau GS, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. <i>J Clin Psychiatry</i>. 2007;68(5):662-668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17503974/pubmed" id="17503974" target="_blank">17503974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12190212">
<a name="12190212"></a>Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. <i>South Med J</i>. 2002;95(8):799-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/12190212/pubmed" id="12190212" target="_blank">12190212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25786075">
<a name="25786075"></a>Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. <i>JAMA Psychiatry</i>. 2015;72(5):438-445. doi:10.1001/jamapsychiatry.2014.3018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/25786075/pubmed" id="25786075" target="_blank">25786075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17195735">
<a name="17195735"></a>McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(1):107-125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17195735/pubmed" id="17195735" target="_blank">17195735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23972700">
<a name="23972700"></a>McClellan J, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(9):976-990. doi:10.1016/j.jaac.2013.02.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23972700/pubmed" id="23972700" target="_blank">23972700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15600384">
<a name="15600384"></a>McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. <i>J Clin Psychiatry</i>. 2004;65(suppl 18):47-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/15600384/pubmed" id="15600384" target="_blank">15600384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16696834">
<a name="16696834"></a>Mendhekar DN, Sunder KR, and Andrade C, “Aripiprazole Use in a Pregnant Schizoaffective Woman,” <i>Bipolar Disord</i>, 2006, 8(3):299-300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/16696834/pubmed" id="16696834" target="_blank">16696834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35695655">
<a name="35695655"></a>Meyer G, Gitahy Falcao Faria C, Beck M, Riutort M, Michel B, Javelot H. Suicidality and psychotic episodes after starting aripiprazole: two case reports. <i>Int Clin Psychopharmacol</i>. 2022;37(5):225-228. doi:10.1097/YIC.0000000000000408<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/35695655/pubmed" id="35695655" target="_blank">35695655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19192469">
<a name="19192469"></a>Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. <i>J Clin Psychiatry</i>. 2009;70(3):318-325. doi:10.4088/jcp.08m04267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19192469/pubmed" id="19192469" target="_blank">19192469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17974864">
<a name="17974864"></a>Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. <i>Am J Geriatr Psychiatry</i>. 2007;15(11):918-931.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17974864/pubmed" id="17974864" target="_blank">17974864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18588606">
<a name="18588606"></a>Miyamoto S, Miyake N, Ogino S, Endo T, Yamaguchi N. Successful treatment of delusional disorder with low-dose aripiprazole. <i>Psychiatry Clin Neurosci</i>. 2008;62(3):369. doi:10.1111/j.1440-1819.2008.01812.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18588606/pubmed" id="18588606" target="_blank">18588606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32670542">
<a name="32670542"></a>Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. <i>Ther Adv Psychopharmacol</i>. 2020;10:2045125320937910. doi:10.1177/2045125320937910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/32670542/pubmed" id="32670542" target="_blank">32670542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moore.2019">
<a name="Moore.2019"></a>Moore GP, Moore MJ. Assessment and emergency management of the acutely agitated or violent adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25329919">
<a name="25329919"></a>Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. <i>JAMA Intern Med</i>. 2014;174(12):1930-1933. doi:10.1001/jamainternmed.2014.5262<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/25329919/pubmed" id="25329919" target="_blank">25329919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8102845">
<a name="8102845"></a>Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study. <i>Arch Gen Psychiatry</i>. 1993;50(9):723-733. doi:10.1001/archpsyc.1993.01820210057007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/8102845/pubmed" id="8102845" target="_blank">8102845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morrato.2012">
<a name="Morrato.2012"></a>Morrato EH. An update on lipid profile screening in second generation antipsychotic users in the USA. <i>Clinical Lipidology</i>. 2012;7(5):509-523. doi:10.2217/clp.12.51</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20187598">
<a name="20187598"></a>Muench J, Hamer AM. Adverse effects of antipsychotic medications. <i>Am Fam Physician</i>. 2010;81(5):617-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/20187598/pubmed" id="20187598" target="_blank">20187598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27811554">
<a name="27811554"></a>Muñoz-Negro JE, Cervilla JA. A systematic review on the pharmacological treatment of delusional disorder. <i>J Clin Psychopharmacol</i>. 2016;36(6):684-690. doi:10.1097/JCP.0000000000000595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/27811554/pubmed" id="27811554" target="_blank">27811554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21346614">
<a name="21346614"></a>Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. <i>J Clin Psychopharmacol</i>. 2011;31(2):174-179. doi:10.1097/JCP.0b013e31820e3db6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21346614/pubmed" id="21346614" target="_blank">21346614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31509359">
<a name="31509359"></a>Mustafa S, Joober R, Iyer S, Shah J, Lepage M, Malla A. Early stabilization of weight changes following treatment with olanzapine, risperidone, and aripiprazole: a 12-month naturalistic study of first episode psychosis. <i>J Clin Psychiatry</i>. 2019;80(5):18m12717. doi:10.4088/JCP.18m12717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/31509359/pubmed" id="31509359" target="_blank">31509359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21720229">
<a name="21720229"></a>Muzyk AJ, Rivelli SK, Gagliardi JP, Revollo JY, Jiang W. A retrospective study exploring the effects of intramuscular aripiprazole on QTc change in agitated medically ill patients. <i>J Clin Psychopharmacol</i>. 2011;31(4):532-534. doi:10.1097/JCP.0b013e318221e63b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21720229/pubmed" id="21720229" target="_blank">21720229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Clinical Excellence (NICE). Bipolar disorder. The NICE guideline on the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. https://www.nice.org.uk/guidance/cg185/evidence/full-guideline-pdf-4840895629. Updated June 2022. Accessed September 28, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26065063">
<a name="26065063"></a>National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2013. https://www.nice.org.uk/guidance/cg155
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/26065063/pubmed" id="26065063" target="_blank">26065063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23362038">
<a name="23362038"></a>Nelson S, Leung JG. Torsades de pointes after administration of low-dose aripiprazole. <i>Ann Pharmacother</i>. 2013;47(2):e11. doi:10.1345/aph.1R387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23362038/pubmed" id="23362038" target="_blank">23362038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15998156">
<a name="15998156"></a>Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. <i>CNS Drugs</i>. 2005;19(suppl 1):1-93. doi:10.2165/00023210-200519001-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/15998156/pubmed" id="15998156" target="_blank">15998156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21413838">
<a name="21413838"></a>Nguyen T, Teoh S, Hackett LP, et al. Placental transfer of aripiprazole. <i>Aust N Z J Psychiatry. </i>2011;45(6):500-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21413838/pubmed" id="21413838" target="_blank">21413838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20520598">
<a name="20520598"></a>Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. <i>Neuropsychopharmacology</i>. 2010;35(9):1997-2004. doi:10.1038/npp.2010.78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/20520598/pubmed" id="20520598" target="_blank">20520598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22854034">
<a name="22854034"></a>Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. <i>Can J Psychiatry</i>. 2012;57(8):512-518. doi:10.1177/070674371205700810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/22854034/pubmed" id="22854034" target="_blank">22854034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28291979">
<a name="28291979"></a>Ninčević Ž, Lasić D, Glavina T, Mikačić M, Carev M, Podrug K. Quetiapine poisoning associated with neuroleptic malignant syndrome, rhabdomyolysis and renal failure: a case report. <i>Psychiatr Danub</i>. 2017;29(1):84-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28291979/pubmed" id="28291979" target="_blank">28291979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24525642">
<a name="24525642"></a>Nordeng H, Gjerdalen G, Brede WR, Michelsen LS, Spigset O. Transfer of aripiprazole to breast milk: a case report. <i>J Clin Psychopharmacol</i>. 2014;34(2):272-275.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24525642/pubmed" id="24525642" target="_blank">24525642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22533871">
<a name="22533871"></a>Nunes LV, Moreira HC, Razzouk D, Nunes SO, Mari Jde J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. <i>J Sex Marital Ther</i>. 2012;38(3):281-301. doi:10.1080/0092623X.2011.606883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/22533871/pubmed" id="22533871" target="_blank">22533871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14565800">
<a name="14565800"></a>O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. <i>Ann Pharmacother</i>. 2003;37(11):1675-1684. doi:10.1345/aph.1D056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/14565800/pubmed" id="14565800" target="_blank">14565800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31067549">
<a name="31067549"></a>Obara K, Fujii A, Arie C, et al. Inhibition of recombinant human acetylcholinesterase activity by antipsychotics. <i>Pharmacology</i>. 2019;104(1-2):43-50. doi:10.1159/000500227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/31067549/pubmed" id="31067549" target="_blank">31067549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17012695">
<a name="17012695"></a>Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. <i>Am J Psychiatry</i>. 2006;163(10):1821-1825. doi:10.1176/ajp.2006.163.10.1821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17012695/pubmed" id="17012695" target="_blank">17012695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37068012">
<a name="37068012"></a>Onggo S, Chang R, Singh A, Lopez K, Chen L, Hah M. Pericarditis associated with aripiprazole: a case report. <i>J Clin Psychopharmacol</i>. 2023;43(3):295-296. doi:10.1097/JCP.0000000000001686<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/37068012/pubmed" id="37068012" target="_blank">37068012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31039482">
<a name="31039482"></a>Oughli H, Lenze EJ, Locke AE, et al. Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole. <i>J Psychiatr Res</i>. 2019;114:67-74. doi:10.1016/j.jpsychires.2019.04.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/31039482/pubmed" id="31039482" target="_blank">31039482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20686147">
<a name="20686147"></a>Oulis P, Mourikis I, Konstantakopoulos G, Papageorgiou SG, Kouzoupis AV. Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.<i> J Neuropsychiatry Clin Neurosci</i>. 2010;22(3):352c.e4-352.e5. doi:10.1176/appi.neuropsych.22.3.352-c.e4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/20686147/pubmed" id="20686147" target="_blank">20686147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27568278">
<a name="27568278"></a>Pacchiarotti I, León-Caballero J, Murru A, et al. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. <i>Eur Neuropsychopharmacol</i>. 2016;26(10):1562-1578.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/27568278/pubmed" id="27568278" target="_blank">27568278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21103170">
<a name="21103170"></a>Padder T, Skodnek K, Hashmi S, et al. Acute akathisia with suicidal ideation associated with low dose aripiprazole. <i>Psychiatry (Edgmont)</i>. 2006;3(4):40-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21103170/pubmed" id="21103170" target="_blank">21103170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17272970">
<a name="17272970"></a>Palakurthi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. <i>Clin Neuropharmacol</i>. 2007;30(1):47-51. doi:10.1097/01.WNF.0000240941.13876.5E<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17272970/pubmed" id="17272970" target="_blank">17272970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20651315">
<a name="20651315"></a>Patel MK, Brunetti L. Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient. <i>Am J Health Syst Pharm</i>. 2010;67(15):1254-1259. doi:10.2146/ajhp090243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/20651315/pubmed" id="20651315" target="_blank">20651315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31325958">
<a name="31325958"></a>Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. <i>BMC Neurol</i>. 2019;19(1):174. Published 2019 Jul 20. doi:10.1186/s12883-019-1385-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/31325958/pubmed" id="31325958" target="_blank">31325958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9735957">
<a name="9735957"></a>Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. <i>Psychiatr Serv</i>. 1998;49(9):1163-1172. doi:10.1176/ps.49.9.1163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/9735957/pubmed" id="9735957" target="_blank">9735957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24688758">
<a name="24688758"></a>Perera MA, Yogaratnam J. De Novo delayed onset hypothermia secondary to therapeutic doses of risperidone in bipolar affective disorder. <i>Ther Adv Psychopharmacol</i>. 2014;4(2):70-74. doi:10.1177/2045125313507740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24688758/pubmed" id="24688758" target="_blank">24688758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19629012">
<a name="19629012"></a>Pessina E, Albert U, Bogetto F, Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.<i> Int Clin Psychopharmacol</i>. 2009;24(5):265-269. doi:10.1097/YIC.0b013e32832e9b91<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19629012/pubmed" id="19629012" target="_blank">19629012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28696131">
<a name="28696131"></a>Peterson E, Forlano R. Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole. <i>Australas Psychiatry</i>. 2017;25(6):614-616. doi:10.1177/1039856217715996<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28696131/pubmed" id="28696131" target="_blank">28696131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26397725">
<a name="26397725"></a>Pinnaka S, Roberto AJ, Giordano A, Siller P, Lapidus K. Aripiprazole-induced transient morning pseudoneutropenia in an 11-year-old male. <i>J Child Adolesc Psychopharmacol</i>. 2016;26(9):858-859. doi:10.1089/cap.2015.0128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/26397725/pubmed" id="26397725" target="_blank">26397725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26509095">
<a name="26509095"></a>Pondé MP, Freire AC. Increased anxiety, akathisia, and suicidal thoughts in patients with mood disorder on aripiprazole and lamotrigine. <i>Case Rep Psychiatry</i>. 2015;2015:419746. doi:10.1155/2015/419746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/26509095/pubmed" id="26509095" target="_blank">26509095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.2019">
<a name="Post.2019"></a>Post RM. Bipolar disorder in adults: Choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19287562">
<a name="19287562"></a>Qureshi SU, Rubin E. Risperidone- and aripiprazole-induced leukopenia: a case report. <i>Prim Care Companion J Clin Psychiatry</i>. 2008;10(6):482-483. doi:10.4088/pcc.v10n0612c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19287562/pubmed" id="19287562" target="_blank">19287562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19111849">
<a name="19111849"></a>Rappaport SA, Marcus RN, Manos G, McQuade RD, Oren DA. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia.<i> J Am Med Dir Assoc</i>. 2009;10(1):21-27. doi:10.1016/j.jamda.2008.06.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19111849/pubmed" id="19111849" target="_blank">19111849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29107566">
<a name="29107566"></a>Reddy B, Ali M, Guruprasad S, Das S. Hypersexuality induced by aripiprazole: Two case reports and review of the literature. <i>Asian J Psychiatr</i>. 2018;38:57-59. doi:10.1016/j.ajp.2017.10.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/29107566/pubmed" id="29107566" target="_blank">29107566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15949658">
<a name="15949658"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi:10.1016/j.schres.2005.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/15949658/pubmed" id="15949658" target="_blank">15949658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27133416">
<a name="27133416"></a>Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. <i>Am J Psychiatry</i>. 2016;173(5):543-546. doi:10.1176/appi.ajp.2015.173501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/27133416/pubmed" id="27133416" target="_blank">27133416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29905899">
<a name="29905899"></a>Ribeiro ELA, de Mendonça Lima T, Vieira MEB, Storpirtis S, Aguiar PM. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. <i>Eur J Clin Pharmacol</i>. 2018;74(10):1215-1233. doi:10.1007/s00228-018-2498-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/29905899/pubmed" id="29905899" target="_blank">29905899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26338693">
<a name="26338693"></a>Robinson DG, Gallego JA, John M, Petrides G, et al. A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. <i>Schizophr Bull</i>. 2015;41(6):1227-1236. doi:10.1093/schbul/sbv125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/26338693/pubmed" id="26338693" target="_blank">26338693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34757514">
<a name="34757514"></a>Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. <i>Eur Child Adolesc Psychiatry</i>. 2022;31(3):425-441. doi:10.1007/s00787-021-01899-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/34757514/pubmed" id="34757514" target="_blank">34757514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24424705">
<a name="24424705"></a>Roffeei SN, Reynolds GP, Zainal NZ, et al. Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone. <i>Hum Psychopharmacol</i>. 2014;29(1):38-45. doi:10.1002/hup.2366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24424705/pubmed" id="24424705" target="_blank">24424705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26218604">
<a name="26218604"></a>Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. <i>Pharmacol Res</i>. 2015;101:74-85. doi:10.1016/j.phrs.2015.07.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/26218604/pubmed" id="26218604" target="_blank">26218604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20180730">
<a name="20180730"></a>Roxanas MG. Pathological gambling and compulsive eating associated with aripiprazole. <i>Aust N Z J Psychiatry</i>. 2010;44(3):291. doi:10.3109/00048670903487282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/20180730/pubmed" id="20180730" target="_blank">20180730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25844991">
<a name="25844991"></a>Rubin DM, Kreider AR, Matone M, et al. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. <i>JAMA Pediatr</i>. 2015;169(4):e150285. doi:10.1001/jamapediatrics.2015.0285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/25844991/pubmed" id="25844991" target="_blank">25844991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22933237">
<a name="22933237"></a>Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). <i>Depress Anxiety</i>. 2012;29(10):850-854. doi:10.1002/da.21996<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/22933237/pubmed" id="22933237" target="_blank">22933237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30672720">
<a name="30672720"></a>Schoemakers RJ, van Kesteren C, van Rosmalen J, Eussen MLJM, Dieleman HG, Beex-Oosterhuis MM. No differences in weight gain between risperidone and aripiprazole in children and adolescents after 12 months. <i>J Child Adolesc Psychopharmacol</i>. 2019;29(3):192-196. doi:10.1089/cap.2018.0111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30672720/pubmed" id="30672720" target="_blank">30672720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30042077">
<a name="30042077"></a>Schneider-Thoma J, Efthimiou O, Huhn M, et al. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. <i>Lancet Psychiatry</i>. 2018;5(8):653-663. doi:10.1016/S2215-0366(18)30177-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30042077/pubmed" id="30042077" target="_blank">30042077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213967">
<a name="19213967"></a>Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. <i>Psychosomatics</i>. 2009;50(1):8-15. doi:10.1176/appi.psy.50.1.8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19213967/pubmed" id="19213967" target="_blank">19213967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21131415">
<a name="21131415"></a>Selvaraj V, Ramaswamy S, Sharma A, Wilson D. New-onset psychosis and emergence of suicidal ideation with aripiprazole. <i>Am J Psychiatry</i>. 2010;167(12):1535-1536. doi:10.1176/appi.ajp.2010.10020238<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21131415/pubmed" id="21131415" target="_blank">21131415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21191308">
<a name="21191308"></a>Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. <i>Int Clin Psychopharmacol</i>. 2011;26(3):130-140. doi:10.1097/YIC.0b013e328341e434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21191308/pubmed" id="21191308" target="_blank">21191308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29128325">
<a name="29128325"></a>She S, Kuang Q, Zheng Y. Aripiprazole-induced tardive dyskinesia in patients with schizophrenia: A case report of twins. <i>Schizophr Res</i>. 2018;197:564-565. doi:10.1016/j.schres.2017.10.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/29128325/pubmed" id="29128325" target="_blank">29128325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20540690">
<a name="20540690"></a>Sheehan JJ, Sliwa JK, Amatniek A, et al. Atypical antipsychotic metabolism and excretion. <i>Current Drug Metabolism.</i> 2010;11:516-525.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/20540690/pubmed" id="20540690" target="_blank">20540690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21645873">
<a name="21645873"></a>Shirani A, Paradiso S, Dyken ME. The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review. <i>Sleep Med</i>. 2011;12(6):591-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21645873/pubmed" id="21645873" target="_blank">21645873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33970023">
<a name="33970023"></a>Shirk DV, Wendel N, Williams SD, Cardiel-Sam H. <i>Letter to the editor:</i> aripiprazole induced angioedema-an unusual cross-reactivity resulting in angioedema. <i>J Child Adolesc Psychopharmacol</i>. 2021;31(5):389. doi:10.1089/cap.2020.0200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/33970023/pubmed" id="33970023" target="_blank">33970023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17390261">
<a name="17390261"></a>Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169. doi:10.1055/s-2007-971169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17390261/pubmed" id="17390261" target="_blank">17390261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721057">
<a name="28721057"></a>Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Ther Clin Risk Manag</i>. 2017;13:757-777. doi:10.2147/TCRM.S117321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28721057/pubmed" id="28721057" target="_blank">28721057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29439776">
<a name="29439776"></a>Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. <i>J Neurol Sci</i>. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/29439776/pubmed" id="29439776" target="_blank">29439776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15564813">
<a name="15564813"></a>Spalding S, Alessi NE, Radwan K. Aripiprazole and atypical neuroleptic malignant syndrome. <i>J Am Acad Child Adolesc Psychiatry</i>. 2004;43(12):1457-1458. doi:10.1097/01.chi.0000142277.95052.94<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/15564813/pubmed" id="15564813" target="_blank">15564813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23343447">
<a name="23343447"></a>Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. <i>Curr Clin Pharmacol</i>. 2014;9(3):310-7. doi:10.2174/15748847113089990051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23343447/pubmed" id="23343447" target="_blank">23343447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28045840">
<a name="28045840"></a>Sridaran R, Nesbit CE. Acute dystonia versus neuroleptic malignant syndrome without fever in an eight-year-old child. <i>Pediatr Emerg Care</i>. 2017;33(1):38-40. doi:10.1097/PEC.0000000000001000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28045840/pubmed" id="28045840" target="_blank">28045840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Steinman.1">
<a name="Steinman.1"></a>Steinman M, Reeve E. Deprescribing. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23083030">
<a name="23083030"></a>Stern AP, Trieu ML. A case of antipsychotic-induced hyperglycemia in a child with insulin dependent diabetes mellitus. <i>J Child Adolesc Psychopharmacol</i>. 2012;22(5):403-404. doi:10.1089/cap.2012.0038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23083030/pubmed" id="23083030" target="_blank">23083030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. doi:10.1345/aph.1L066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stovall.2019">
<a name="Stovall.2019"></a>Stovall J. Bipolar mania and hypomania in adults: Choosing pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18591574">
<a name="18591574"></a>Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. <i>Am J Geriatr Psychiatry</i>. 2008;16(7):537-550. doi: 10.1097/JGP.0b013e318165db77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18591574/pubmed" id="18591574" target="_blank">18591574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30192094">
<a name="30192094"></a>Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. <i>World Psychiatry</i>. 2018;17(3):341-356. doi:10.1002/wps.20567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30192094/pubmed" id="30192094" target="_blank">30192094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.2019">
<a name="Stroup.2019"></a>Stroup TS, Marder S. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Suchowersky.2019">
<a name="Suchowersky.2019"></a>Suchowersky O. Huntington disease: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Suh.2019">
<a name="Suh.2019"></a>Suh KN, Keystone JS. Treatment of delusional infestation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 8, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24101361">
<a name="24101361"></a>Sweeney EB, Lawlor BA. Case series: extrapyramidal symptoms associated with use of aripiprazole in older adults. <i>Int J Geriatr Psychiatry</i>. 2013;28(11):1208-1210. doi:10.1002/gps.3964<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24101361/pubmed" id="24101361" target="_blank">24101361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30398998">
<a name="30398998"></a>Szota AM, Araszkiewicz AS. The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors. <i>Int Clin Psychopharmacol</i>. 2019;34(1):1-8. doi:10.1097/YIC.0000000000000244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30398998/pubmed" id="30398998" target="_blank">30398998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28044008">
<a name="28044008"></a>Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. <i>Schizophr Bull</i>. 2017;43(4):862-871. doi:10.1093/schbul/sbw171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28044008/pubmed" id="28044008" target="_blank">28044008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31688404">
<a name="31688404"></a>Taleb S, Zgueb Y, Ouali U, Jomli R, Kort Y, Nacef F. Drug reaction with eosinophilia and systemic symptoms syndrome related to aripiprazole therapy. <i>J Clin Psychopharmacol</i>. 2019;39(6):691-693. doi:10.1097/JCP.0000000000001138<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/31688404/pubmed" id="31688404" target="_blank">31688404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27828697">
<a name="27828697"></a>Tarraf C, Naja WJ. Aripiprazole-induced hyperlipidemia: an update. <i>Prim Care Companion CNS Disord</i>. 2016;18(4):10.4088/PCC.16r01958. doi:10.4088/PCC.16r01958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/27828697/pubmed" id="27828697" target="_blank">27828697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23835329">
<a name="23835329"></a>Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. <i>Diabetes</i>. 2013;62(9):3232-3240. doi:10.2337/db13-0430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23835329/pubmed" id="23835329" target="_blank">23835329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11249804">
<a name="11249804"></a>Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. <i>Bipolar Disord</i>. 2000;2(3, pt 2):261-268. doi:10.1034/j.1399-5618.2000.20307.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/11249804/pubmed" id="11249804" target="_blank">11249804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32448188">
<a name="32448188"></a>Torrico T, Kiai N, Meza C, Salam MT, Abdijadid S. Suspected aripiprazole-induced neutropenia in a geriatric patient: a case report. <i>BMC Geriatr</i>. 2020;20(1):179. doi:10.1186/s12877-020-01514-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/32448188/pubmed" id="32448188" target="_blank">32448188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22626633">
<a name="22626633"></a>Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. <i>Br J Psychiatry</i>. 2012;201(1):52-56. doi:10.1192/bjp.bp.111.105189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/22626633/pubmed" id="22626633" target="_blank">22626633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25838319">
<a name="25838319"></a>Tseng PT, Chang YC, Chang CH, et al. Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review. <i>Int J Psychiatry Med</i>. 2015;49(1):35-43. doi:10.2190/PM.49.1.c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/25838319/pubmed" id="25838319" target="_blank">25838319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27028982">
<a name="27028982"></a>Uguz F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. <i>J Clin Psychopharmacol</i>. 2016;36(3):244-252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/27028982/pubmed" id="27028982" target="_blank">27028982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473482">
<a name="10473482"></a>van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. <i>BMJ</i>. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/10473482/pubmed" id="10473482" target="_blank">10473482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17401555">
<a name="17401555"></a>van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. <i>Eur J Clin Pharmacol</i>. 2007;63(6):627-631. doi:10.1007/s00228-007-0294-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17401555/pubmed" id="17401555" target="_blank">17401555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18348593">
<a name="18348593"></a>van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. <i>J Clin Psychiatry</i>. 2008;69(3):472-479. doi:10.4088/jcp.v69n0320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18348593/pubmed" id="18348593" target="_blank">18348593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29075885">
<a name="29075885"></a>Vázquez-Bourgon J, Pérez-Iglesias R, Ortiz-García de la Foz V, Suárez Pinilla P, Díaz Martínez Á, Crespo-Facorro B. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. <i>Psychopharmacology (Berl)</i>. 2018;235(1):245-255. doi:10.1007/s00213-017-4763-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/29075885/pubmed" id="29075885" target="_blank">29075885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30700975">
<a name="30700975"></a>Ventriglio A, Baldessarini RJ, Vitrani G, et al. Metabolic syndrome in psychotic disorder patients treated with oral and long-acting injected antipsychotics. <i>Front Psychiatry</i>. 2019;9:744. doi:10.3389/fpsyt.2018.00744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/30700975/pubmed" id="30700975" target="_blank">30700975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23858394">
<a name="23858394"></a>Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. <i>Tremor Other Hyperkinet Mov (N Y)</i>. 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23858394/pubmed" id="23858394" target="_blank">23858394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21532364">
<a name="21532364"></a>Watanabe N, Kasahara M, Sugibayashi R, et al. Perinatal Use of Aripiprazole: A Case Report. <i>J Clin Psychopharmacol.</i> 2011;31(3):377-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21532364/pubmed" id="21532364" target="_blank">21532364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27780320">
<a name="27780320"></a>Welten CC, Koeter MW, Wohlfarth TD, et al. Early nonresponse in the antipsychotic treatment of acute mania: a criterion for reconsidering treatment? Results from an individual patient data meta-analysis. <i>J Clin Psychiatry</i>. 2016;77(9):e1117-e1123. doi:10.4088/JCP.15r10051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/27780320/pubmed" id="27780320" target="_blank">27780320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24919175">
<a name="24919175"></a>Wen XJ, Wang LM, Liu ZL, Huang A, Liu YY, Hu JY. Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. <i>Braz J Med Biol Res</i>. 2014;47(7):605-616. doi:10.1590/1414-431x20143672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24919175/pubmed" id="24919175" target="_blank">24919175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22461918">
<a name="22461918"></a>Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. <i>West J Emerg Med</i>. 2012;13(1):26-34. doi:10.5811/westjem.2011.9.6866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/22461918/pubmed" id="22461918" target="_blank">22461918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21288069">
<a name="21288069"></a>World Federation of Societies of Biological Psychiatry; Ihl R, Frölich L, Winblad B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. <i>World J Biol Psychiatry</i>. 2011;12(1):2-32. doi:10.3109/15622975.2010.538083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21288069/pubmed" id="21288069" target="_blank">21288069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25497507">
<a name="25497507"></a>Wu CY, Mitchell SR, Seyfried LS. Quetiapine-induced hyperglycemic crisis and severe hyperlipidemia: a case report and review of the literature. <i>Psychosomatics</i>. 2014;55(6):686-691. doi:10.1016/j.psym.2014.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/25497507/pubmed" id="25497507" target="_blank">25497507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23237061">
<a name="23237061"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. <i>Bipolar Disord</i>. 2013;15(1):1-44. doi:10.1111/bdi.12025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23237061/pubmed" id="23237061" target="_blank">23237061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord.</i> 2018;20(2):97-170. doi:10.1111/bdi.12609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23686053">
<a name="23686053"></a>Yavuz KF, Ulusoy S, Alnıak İ. Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington's disease. <i>J Neuropsychiatry Clin Neurosci</i>. 2013;25(2):E31. doi:10.1176/appi.neuropsych.12040097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23686053/pubmed" id="23686053" target="_blank">23686053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24563196">
<a name="24563196"></a>Yeh TC, Lin YC, Chen LF, et al. Aripiprazole treatment in a case of amphetamine-induced delusional infestation. <i>Aust N Z J Psychiatry</i>. 2014;48(7):681-682. doi:10.1177/0004867414525849<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24563196/pubmed" id="24563196" target="_blank">24563196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31433335">
<a name="31433335"></a>Yeh TC, Tzeng NS, Li JC, et al. Mortality risk of atypical antipsychotics for behavioral and psychological symptoms of dementia: a meta-analysis, meta-regression, and trial sequential analysis of randomized controlled trials. <i>J Clin Psychopharmacol</i>. 2019;39(5):472-478. doi:10.1097/JCP.0000000000001083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/31433335/pubmed" id="31433335" target="_blank">31433335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19701065">
<a name="19701065"></a>Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. <i>Obstet Gynecol.</i> 2009;114(3):703-713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19701065/pubmed" id="19701065" target="_blank">19701065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24446539">
<a name="24446539"></a>Zhang Y, Dai G. Efﬁcacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. <i>Hum Psychopharmacol</i>. 2012;27(6):605-614. doi:10.1002/hup.2270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/24446539/pubmed" id="24446539" target="_blank">24446539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28936184">
<a name="28936184"></a>Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to antipsychotic medication: a systematic review. <i>Front Psychiatry</i>. 2017;8:165. doi:10.3389/fpsyt.2017.00165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/28936184/pubmed" id="28936184" target="_blank">28936184</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13180 Version 651.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
